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ABSTRACT
MECHANISMS AND INTERVENTION STRATEGIES FOR ALCOHOL AND
HIV-ANTIRETROVIRAL THERAPY-INDUCED LIVER INJURY

Hridgandh Donde
November 9th 2015
Section I: Chronic alcohol consumption is a leading cause of liver disease and
liver-related death worldwide. Alcoholic liver disease includes, hepatic steatosis,
steatohepatitis and ultimately fibrosis and cirrhosis. Emerging evidence has
established the important role of the “gut-liver” axis in the development of
alcoholic liver disease (ALD). Our recent work indicated that chronic alcohol
induced perturbations in the gut microbiome and consequent changes in fatty
acids have a major impact on the development of intestinal barrier dysfunction
and ALD. The aim of this study was to investigate whether treatment with
tributyrin - a butyrate prodrug results in protection against ALD in terms of
hepatic steatosis, inflammation and injury. Tributyrin is a triglyceride that is
rapidly absorbed and metabolized to butyrate. Moreover, it has more favorable
pharmacokinetics compared with butyrate with low toxicity.
In the present study, we have used a mouse model of ALD to examine the
effects of Tributyrin oral administration on ethanol-induced changes in intestinal
permeability and hepatic steatosis, inflammation and injury. 8–10-week old
C57BL/6 male mice were chronically pair-fed the Lieber-DeCarli liquid diet
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containing alcohol or isocaloric maltose dextrin. Tributyrin was administered to a
sub-group of alcohol-fed animals by oral gavage (2g/kg) for 5 days/week to
assess its effects.
Tributyrin attenuated the ethanol-induced gut barrier dysfunction, as
shown by the significant reduction in endotoxemia. Mechanisms of chronic
alcohol-induced gut-barrier dysfunction were examined by immunohistochemical
analyses of the ileum section of mice chronically fed alcohol. Specifically, alcohol
induced a robust down-regulation of intestinal tight junction proteins ZO-1 and
occludin which was markedly attenuated by tributyrin administration. Liver
histological analysis showed a significant decrease in ethanol-induced hepatic
steatosis. Tributyrin also prevented the ethanol-induced down-regulation of
hepatic CPT-1, a key enzyme in free fatty acid β-oxidation, with a resultant
decrease in hepatic triglycerides and free fatty acids. To further elucidate the
mechanism by which tributyrin prevents hepatic steatosis, we performed
experiments using primary hepatocytes. Hepatocytes were treated with alcohol
and with/without pre-treatment with butyrate. Alcohol-induced downregulation of
CPT-1 gene expression was significantly prevented by butyrate. Butyrate is a
known HDAC inhibitor. Hence promoter histone acetylation state was
investigated. In this regard, acetylation of histone 3 lysine 9 (H3K9), a critical
feature of the active promoter state was significantly increased by butyrate and
was essentially mediated by the p300-histone acetyltransferase. Increased
acetylation leads to an open chromatin configuration causing increased
recruitment of co-activators and TF such as PGC-1 and Sp-1 at the CPT-1
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promoter. Additionally RNA-Pol II binding was also increased by butyrate pretreatment in alcohol treated hepatocytes. These data suggest that butyrate, by
acting as an HDAC inhibitor, induces promoter histone acetylation leading to the
transcriptional activation of CPT-1 under pathologic conditions of alcohol
exposure.
Butyrate has been shown to have beneficial effects by decreasing obesityassociated inflammation, and insulin resistance. Hence, its effects on alcohol
induced hepatic inflammation were also investigated. F4/80 staining of liver
sections revealed increased macrophage infiltration in 2 weeks of alcohol feeding
whereas tributryrin administration markedly blocked macrophage infiltration.
Tributyrin administration attenuated the ethanol mediated pro-inflammatory
cytokine TNF-α mRNA expression. Alcohol-induced neutrophil infiltration was
also significantly suppressed by tributyrin administration. Neutrophil infiltration
was further confirmed by MPO activity. Tributyrin administered mice had a
significant drop in MPO activity as compared to alcohol-fed mice at 7 weeks but
not in 2 weeks. Inflammatory chemokine and cytokine such as CXCL-2 (MCP-1)
and CCL-2 (MIP-2) mRNA were significantly upregulated in alcohol-fed mice and
tributryrin administration significantly attenuated alcohol-induced induction of
these pro-inflammatory chemokines. Notably, tributryrin also significantly
attenuated liver injury as seen by a decrease in serum AST & ALT levels. Hence,
the present work demonstrates that tributyrin may be useful in preventing the
ethanol-induced pathogenic changes in the “gut-liver” axis and may prove to be a
useful therapy for the prevention/treatment of ALD.
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Section II: HIV protease inhibitors (HIV-PIs) are the major components of the
highly active anti-retroviral therapy (HAART) and have been successfully used in
the treatment of HIV-1 infection in the past two decades. However prolonged use
of HAART is known to cause hepatotoxicity. Hence it is highly relevant to study
the underlying mechanisms in HAART induced hepatotoxicity that can negatively
impact treatment outcomes. One of the known mechanisms of hepatotoxicity
caused due to HIV-PIs drugs is endoplasmic reticulum (ER) stress and
subsequent activation of unfolded protein response (UPR) leading to dysregulation of hepatic lipid metabolism. Our recent work shows that PDE4/cAMP
metabolism plays a significant role in alcohol-induced hepatic steatosis and
injury. Hence in the present study, we examined the potential mechanisms
underlying HIV-PI induced hepatic ER stress and toxicity with a particular
emphasis on the pathogenic role of PDE4 family of enzymes.
The effects of clinically used HIV-PIs [Ritonavir and Lopinavir] were
examined both in a rat hepatoma cell line (H4IIE). The data obtained from these
studies demonstrated that Ritonavir and Lopinavir in combination led to a
significant loss of hepatocyte survival. Notably, inhibition of PDE4 by a specific
PDE4-inhibitor, rolipram, markedly attenuated hepatotoxicity induced by PI
treatments. Examination of the mechanistic role of PDE4 showed that PDE4
inhibition significantly decreases the PIs-induced expression of the ER stress
related proteins CHOP, ATF-4 and -3. Furthermore, examination of the
PDE4/cAMP-regulated downstream signaling demonstrated the involvement of
cAMP PKA (protein kinase A). Hence, effect of H-89 (PKA inhibitor) was
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examined in hepatocytes treated with HIV-PI and rolipram. PKA inhibition
significantly reversed the rolipram protective effect leading to re-expression of
ER-stress related genes.
Fas/FasL signaling plays a critical role in drug-induced hepatotoxicity and
cell death Hence activation of hepatotoxic Fas/FasL signaling in HIV-PI induced
hepatotoxicity was investigated. Combination of Rit+Lop significantly upregulated FasL and Fas expression in H4IIE rat hepatoma cell line.
Commensurate with the increase in FasL and Fas, PDE4 expression was also
increased with Rit+Lop treatment. Notably PDE4 inhibition down-regulated Fas
and FasL mRNA and protein expression induced by HIV PIs whereas PKA
inhibitor H-89 significantly reversed the rolipram effect on Fas and FasL
expression. Taken together, these data strongly support and identify a
pathogenic/mechanistic role for PDE4 regulated cAMP-PKA in the development
of HIV-PI induced ER-stress and FasL mediated cell death leading to hepatic
steatosis and injury.
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SECTION I
DETERMINE THE EFFECT OF TRIBUTYRIN, A DIETARY
BUTYRATE PRO-DRUG ON ALCOHOL INDUCEDA. ALTERATIONS IN GUT-LIVER AXIS & CONSEQUENT LIVER
INJURY
B. HEPATIC CHEMOKINE EXPRESSION, LEUKOCYTE
RECRUITMENT & LIVER INJURY
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INTRODUCTION
Alcoholic Liver Disease – General Overview
Alcohol abuse exacts a major toll on health and health costs in the United
States. The overall costs of alcohol abuse in the United States are estimated in
some studies to be approximately $185 billion annually. Moreover, excessive
alcohol consumption is the third leading preventable cause of death in the United
States. One to two million people in the U.S. are thought to have alcoholic liver
disease (ALD) and approximately 14,000 people die of cirrhosis each year. In the
Western world, alcohol remains the single most significant cause of liver disease,
responsible for between 40-80 percent of cases of cirrhosis. Alcoholic hepatitis is
an important cause of morbidity, mortality, and health care costs in the United
States and worldwide.
Clinically, the spectrum of ALD comprises of hepatic steatosis (fatty liver),
steatohepatitis (hepatic inflammation) followed by fibrosis and cirrhosis
sometimes leading to hepatocellular carcinoma. Amongst various stages of ALD,
hepatic steatosis (fat accumulation) is an initial stage of ALD seen in >90% of the
heavy alcohol drinkers [1]. Abstinence from alcohol can lead to significant
reversal of lipid accumulation in the liver. The progression from hepatic steatosis
to steatohepatitis occurs in approximately 35% of the alcoholics. Pathologies
such as neutrophil infiltration, kupffer cell activation, ballooning of the hepatocyte
are indicative of alcohol-mediated steatohepatitis [2]. Sustained inflammation and
2

steatosis further lead to fibrosis and cirrhosis. Finally, 1-5% of the cirrhotic
patients develop hepatocellular carcinoma [2]. Interestingly, only 35% of the
heavy drinkers develop advanced stages of ALD, which indicates that other cofactors are also involved. This includes obesity, drugs, gender, cigarette smoking
and dietary factors [3-5]. Additionally, chronic alcohol consumption has
synergistic effects with viruses such as Hepatitis Virus B and C as well as Human
Immunodeficiency Virus.
Notably, despite decades of research on understanding the pathogenesis
of liver disease there is no FDA approved therapy available to treat any
form/stages of ALD. Hence it is highly relevant to study the mechanisms of the
development of ALD. This would allow investigation of the potential therapeutic
intervention(s) to reverse/prevent ALD and forms the basis of this dissertation
proposal.
Alcohol-induced Hepatic Steatosis (fatty liver) and its Mechanisms
Steatosis is the initial, most frequent hepatic manifestation that occurs in
response to acute as well as chronic ethanol consumption. Although alcoholinduced hepatic steatosis initially was considered to be a relatively benign state,
it is now regarded as a significant risk factor for more progressive disease.
Individuals with alcohol-induced hepatic steatosis are predisposed to develop
advanced liver pathology, including alcoholic steatohepatitis (ASH), hepatic
fibrosis, cirrhosis and even hepatocellular carcinoma. Hepatic steatosis is
characterized by accumulation of lipid droplets (mainly triglycerides,
phospholipids and cholesterol esters), which are formed by the esterification of
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free fatty acids (FFA) and glycerol in the hepatocyte cytoplasm. Alcohol-induced
hepatic lipid accumulation is caused as a result of increased de novo lipogenesis,
decreased fatty acid oxidation and transport of lipids via very low-density
lipoprotein (VLDL) [6].
Alcohol and Hepatic β-oxidation
Alcohol consumption is known to cause disturbances in the fatty oxidation
leading to excess lipid accumulation in the liver. Oxidation of fatty acids takes
place in different organelles namely, mitochondria and peroxisomes specific for
β-oxidation and ω-oxidation [7, 8]. During fatty acid oxidation, lipids are targeted
for either esterification or to mitochondrial β-oxidation. The long chain fatty acids
are incorporated into the mitochondria and are oxidized by β-oxidation process.
In the β-oxidation process fatty acids are transported from the cytosol to the
mitochondrial matrix. These fatty acids are initially activated by coenzyme A in
the cytoplasm, in the presence of fatty acyl-CoA synthetase [9]. Further, fatty
acyl-CoA is then converted to fatty acyl carnitine by carnitine palmitoyl
transferase (CPT-1) in the outer mitochondrial membrane. Subsequently,
Carnitine translocase shuttles the fatty acyl carnitine across the inner
mitochondrial membrane [9]. Finally acetyl-CoA formed in the mitochondrial
matrix via beta-oxidation feeds into tricarboxylic acid cycle thus completing the
oxidation to carbon dioxide and generating energy for the liver [10]. CPT-1 is the
critical rate-limiting step in the β-oxidation pathway. Two isoforms of CPT-1 has
been discovered [11, 12]. L-CPT-1 or liver isoform is expressed in most of the
tissues including liver, kidney and pancreatic β cells whereas M-CPT-1 or muscle
4

isoform of CPT-1 is expressed in heart, skeletal muscle and adipose tissue [12,
13].
Under normal conditions, CPT-1 controls approximately 80% of βoxidation process in the liver and hence decrease in its expression is a crucial
event in the hepatic fat accumulation [14]. Indeed, it has been shown that
normalization of CPT-1 expression alone is sufficient to increase fatty acid
oxidation and attenuate hepatic steatosis [15]. Specifically, these studies showed
that a moderate increase in CPT-1 expression and activity is able to substantially
reduce the hepatic TG burden on either a standard or high-fat diet.
Under pathologic conditions of both chronic and binge alcohol
consumption, CPT-1 expression is significantly down regulated leading to hepatic
steatosis [16, 17]. Importantly, increase in CPT-1 expression by resveratrol and
zinc have shown to prevent chronic ethanol mediated effects [18, 19].
Additionally, our binge alcohol feeding model has documented that prevention of
ethanol induced decrease in CPT-1 expression markedly attenuates hepatic
triglyceride accumulation, steatosis, and injury [17].
Peroxisomal β-oxidation
Peroxisomes are ubiquitous organelles having important metabolic
functions such as β-oxidation of very long-chain α and β fatty acids (VLCFA), αand β-oxidization of long branched chain fatty acids, synthesis of cholesterol and
ether lipids[20-22]. Mechanistically, peroxisomal biogenesis occurs via de novo
synthesis from the endoplasmic reticulum (ER) or via increase in number through
growth and division [23-25]. Pharmacoloigcal agents such as fenofibrate, a
5

peroxisome proliferator-activated receptor-α agonist and SCFA butyrate were
shown to alleviate fatty liver by increasing the peroxisomal abundance. Although
in a NAFLD mice model it has been shown that peroxisomal b-oxidation is
critically involved in lipid accumulation and contributes to fatty liver disease [26],
similar studies are lacking in ALD.

Regulation of CPT-1 gene expression and function: Relevance to alcoholinduced hepatic steatosis
Role of Peroxisome proliferator-activated receptor-alpha (PPAR-α)
PPAR-α is a nuclear hormone receptor which is abundantly expressed in
the tissues such as liver and muscle that have high capacity for fatty acid
oxidation such as liver and muscle [27]. Long chain fatty acids are ligands of
PPAR-α. Upon ligand binding PPAR-α dimerizes with retinoid X receptors (RXR)
at the PPAR response element (PPRE) site in the first intron of the CPT-1 gene
[28]. Emerging evidence has shown that fibrates or other PPAR-α agonists can
attenuate diet-induced fatty liver [29]. Several genes involved in transport and
release of free fatty acids as well as in mitochondrial and peroxisomal fatty acid
β-oxidation pathways [30] including CPT-1 are regulated by PPAR-α [31-33].
However, CPT-1 can also be regulated in a PPAR-α independent manner [34,
35].
Alcohol metabolism both in vivo and in vitro inhibits PPAR-α activation
[36]. Previous studies by Fischer et al. [37] have shown that mice chronically fed
alcohol decrease RXR-α protein levels reducing DNA binding of the PPAR6

α/RXRα heterodimer. This led to a decrease in PPAR-α regulated genes in the
liver resulting in the development of fatty liver. Further, in these studies, a potent
PPAR-α agonist - WY14,643 was observed to prevent the accumulation of
hepatic fat in the alcohol-fed mice by increasing the PPAR-α expression as well
as by increasing the ability of PPAR-α/RXR-α heterodimer complex to bind to the
consensus DNA response element (PPRE). Similarly, Nanji et al [38] also
showed that intragastric ethanol infusion causes down-regulation of PPAR-α
activity leading to fatty liver, which was reversed by clofibrate, a PPAR-α agonist.
These studies document the role of PPAR-α in the development of alcohol
induced fatty liver.
Role of transcriptional factors HNF4α, CREB, Sp-1
Hepatocyte nuclear factor 4α (HNF4α) plays a critical role in the
maintenance of hepatocyte phenotype as well as in the regulation of several
metabolic genes involved in gluconeogenesis, bile acids synthesis, conjugation
and transport. HNF4α acts as a significant transcription factor in the regulation of
CPT-1 gene expression. Liver specific knockout of HNF4α develop
hepatomegaly and accumulation of glycogen and lipids [39, 40]. Moreover,
Talianidis et al., has shown that liver specific HNF4α knockout mice had 50%
reduction in the CPT-1 expression[41]. In this study, recruitment of PPAR-α on
CPT-1 promoter was independent of HNF4α. However the lack of induction of
CPT-1 gene expression in HNF4a KO suggests that co-operation between
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activated PPAR-α and HNF4α is essential for proper regulation of CPT-1 gene
expression [41].
CREB has also been demonstrated to be a transcription factor that
participates in the activation of CPT-1 gene expression [42]. CREB has been
shown to bind the CPT-1 promoter region at a cAMP-responsive unit (CRU) and
is comprised of two cis-acting elements - a DR1 motif and a CRE-like element
(TGACG). Importantly, it has been demonstrated that both CREB and HNF4α
bind to the CPT-1-I promoter. Binding of both CREB and HNF4α is essential for
cAMP responsive CPT-1 gene expression [42]. These data also suggest that
besides PPARα, HNF4α can also cooperate with CREB during the transcriptional
activation of CPT-1 gene expression. However the effect of alcohol on HNF4-α
and CREB mediated transcriptional regulation of CPT-1 remains largely
undetermined.
It has been shown that the transcription factors Sp1, Sp3 and nuclear
factor Y (NF-Y) bind to sites in the CPT-1 proximal promoter and participate in
the developmental and hormonal control of CPT-1 transcriptional regulation as
well as basal gene expression [43]. A recent study showed that plant flavonoids
ingredients such as Ginkgo biloba extract up-regulate CPT-1 through increased
Sp1 binding leading to enhanced fatty acid β-oxidation [44].
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Role of Co-activators and Co-repressor
Peroxisome proliferator-activated receptor-γ coactivator (PGC-1)
Peroxisome proliferator-activated receptor-γ co-activator (PGC-1) act as a
co-activator for several fatty acid oxidation genes, and particularly plays a critical
role in the transcriptional activation [35]. The role of PGC-1 as a critical regulator
of CPT-1 gene expression is clearly documented by the findings that show that
overexpression of PGC-1 alone is sufficient to induce CPT-1 transcription [45].
Co-activator function of PGC-1 is activated via its deacetylation which is effected
by the atypical HDAC – Sirtuin 1 (Sirt1) [46, 47]. Functionally, activated PGC-1
interacts/binds and co-activates nuclear receptor transcription factor PPAR-α as
well as non-nuclear transcription factor HNF4α during the transcriptional
activation of the CPT-1 gene [41]. As a co-activator, upon binding the respective
transcription factors, PGC-1 binds and recruits histone acetyltransferase (HAT)
proteins including CREB-binding protein/p300 and steroid receptor coactivator-1
(SRC-1). Recruitment of HATs by PGC-1 increases promoter histone acetylation
and remodeling of the chromatin that is transcriptionally permissive leading to
CPT-1 gene transcription [48]
With regards to alcohol consumption Leiber’s group has shown that PGC1 mRNA and protein expression were significantly down regulated during chronic
alcohol feeding [49]. These data support the notion that alcohol-induced
decrease in PGC-1 expression is a major pathogenic mechanism that contributes
to the decrease in CPT-1 gene expression and development of hepatic steatosis.
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Role of Epigenetic Mechanisms in the Regulation of CPT-1 gene expression
Promoter histone acetylation
Gene expression is dynamically regulated by chromatin modifications on
histone tails, and histone acetylation promotes transcription, whereas histone
deacetylation negatively regulates transcription. Steady-state levels of acetylation
result from the balance between the opposing activities of histone
acetyltransferases (HATs) and HDACs. Transcriptional activation of CPT-1 has
been demonstrated to be influenced by both HATs as well as HDACs [17].
HATs - particularly, CBP/p300 and SRC-1 can be recruited to the CPT-1 gene by
PGC-1 co-activator that increases promoter histone acetylation and
transcriptional activation [50] In contrast, HDACs - particularly HDAC3 can also
be recruited to the CPT-1 promoter by the co-repressor N-CoR that decreases
promoter histone acetylation and transcriptional activation [50]. Work done by
our group has demonstrated that increase in HDAC3 expression and consequent
N-CoR-HDAC3 mediated down-regulation of CPT-1 expression is the key
epigenetic mechanism that underlies binge alcohol induced hepatic steatosis and
injury [17]. Moreover, the data obtained from this work also demonstrated that by
targeting HDAC3 activity, the binge alcohol-induced decrease in CPT-1 can be
prevented and hepatic steatosis markedly attenuated [17]. Importantly, these
data also strongly implicated that targeting HDAC activity represents a potential
therapeutic approach in the treatment of binge alcohol-induced hepatic steatosis
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Role of Lipogenesis in Alcohol-induced hepatic steatosis
Sterol regulatory element-binding proteins (SREBPs)
Another mechanism that underlies the development of hepatic steatosis is
lipogenesis. Majority of the enzymes and proteins involved in lipogenesis caused
by alcohol are regulated by SREBPs. When activated, SPREBPs that are bound
to the endoplasmic reticulum are released into the nucleus. SREBPs plays a
critical role in regulating the synthesis of cholesterol, fatty acids and triglycerides
in liver by modulating the activation of more than 30 genes in the liver including
fatty acid synthase, ACC, stearoyl-CoA desaturase, ATP citrate lyase, and malic
enzyme. Several studies have shown the involvement of SREBP-1 in the
progression of fat accumulation using in vivo as well as in vitro systems. [51]
During alcohol feeding increased levels of SREBP-1 protein and mRNA was
observed in alcohol-fed mice [52]. Metabolism of alcohol to acetaldehyde
increases the formation of mature SREBP-1 protein enhancing fat production
(hepatic lipogenesis) leading to fatty liver.
Mammalian sirtuin-1 (SIRT-1)
SIRT1, a NAD+ - dependent class III histone deacetylase protein is a
metabolic master regulator. SIRT-1 plays an important role in regulating lipid
metabolism and inflammation by targeting the acetylation status of various
targets such as histones, transcriptional regulators and their co-activators [5355]. Alcohol consumption down-regulates SIRT-1 in hepatic cells and tissues
leading to excess fat accumulation and inflammatory responses which
progresses to alcoholic fatty liver disease (AFLD) [49, 56-58]. SIRT-1 has been
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shown to bind to Sterol regulatory element-binding proteins (SPREBP-1)
resulting in its inactivation via deacetylation. Alcohol consumption reduces the
level of SIRT-1 resulting in the higher levels of acetylated nuclear form of
SREBP-1c causing increased fat production in the liver. Acute and chronic
alcohol consumption increases the expression of several SREBP-1 regulated
fatty acid biogenesis related enzymes leading to excess hepatic lipid
accumulation. Importantly, SREBP-1 KO mice were significantly protected from
AFLD [59]. SIRT1 also de-acetylates PGC-1 in at least 13 lysines at different
domains of the protein[60]. SIRT1 directly interacts with and maintains PGC-1 in
the deacetylated active form bound to the chromatin thus increasing the rate of
transcription of CPT-1 [46, 47]. This indicates that PGC-1 could undergo cycles
of acetylation and deacetylation that are SIRT1 activity dependent [60].
Additionally, SIRT-1 positively regulates PPAR-α. As mentioned before, PGC-1
co-activates with PPAR-α to induce mitochondrial fatty acid oxidation enzymes.
Hence disruptions in the regulation of PPAR-α and PGC-1 due to downregulation of SIRT-1 have been implicated in the development of AFLD in
animals [61-64].
Alcohol-induced hepatic inflammation and injury and its Mechanisms
A major factor responsible for the development of alcoholic liver disease is
immune dysregulation and increased production of pro-inflammatory
cytokines/chemokines which leads to chronic hepatic inflammation. Liver
inflammation is associated with hepatomegaly as well as increased infiltration of
granulocytes, monocytes and lymphocytes.
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Role of kupffer cell activation by LPS in alcohol-induced liver inflammation
and injury
Several reports have shown that chronic alcohol abuse leads to an
increase in gram-negative bacteria in the intestine. Additionally, alcohol is known
to disrupt the gut barrier function by decreasing tight junction protein expression
in the intestine and causing endotoxemia by lipopolysaccharide (LPS) release in
the systemic circulation [65, 66]. Endotoxin is recognized by hepatic
macrophages (kupffer cells) in the portal circulation and is removed from the
systemic circulation. In the liver, exposure of LPS to kupffer cells results in
kupffer cell activation leading to the production of inflammatory cytokines such as
TNF-α and reactive oxygen species (ROS). These inflammatory cytokines and
ROS further activate other liver cells such as hepatocytes, stellate cells and
endothelial cells and enhance LPS induced liver damage[67]. Our lab and
several studies have shown that LPS inducible TNF-α production is increased in
chronic alcoholics and in alcohol-fed animals [68, 69]. Role of TNF-α in alcoholic
liver disease is further documented by McClain et al. where elevated serum
levels of TNF-α inducible cytokines and chemokines including IL-6, IL-8 and IL18 were reported in alcoholic hepatitis (AH) patients [70]. Notably, alcohol
administration to TNF-α knockout mice did not develop liver injury [71],
confirming the pathogenic role of inflammation in the development of ALD.
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Role of Toll-Like receptors (TLRs) in alcohol-induced hepatic inflammation
and injury
TLRs are pattern recognizing receptors that sense pathogen-derived
molecules as well as host-derived danger signals [72, 73]. TLRs are widely
expressed on hepatocytes as well as kupffer cells. Out of 10 different TLRs,
TLR4 is known to be highly relevant in ALD and is widely studied. LPS binds to
TLR4 and activates the production of inflammatory cytokines suggesting that
TLRs play a critical role in the pathophysiology of various liver disease [74].
LPS/TLR4 signaling pathway activates transcription factors such as NF-kB that
induces pro-inflammatory cytokines such as IL-6, IL-8 and TNF-α leading to liver
injury [75, 76]. Exposure to LPS during alcohol consumption results in upregulation of TLR-4 expression on the Kupffer cells as well as other cell types in
the liver. This LPS/TLR4 signaling plays an important role in the pathogenesis of
ALD [77].
Role of Monocyte Chemoattractant Protein-1 (MCP-1) and adhesion
molecules in alcohol-induced hepatic inflammation and injury
In addition to the role of TLR4/LPS signaling pathway and TNFproduction, chemokines and adhesion molecules are also equally responsible
for the development of chronic alcohol induced liver injury [78, 79]. Neutrophil
infiltration and monocytes recruitment in the liver is associated with chronicalcohol induced liver injury. Chemokine such as CCL2 also referred to as
monocyte chemotactic peptide-1 (MCP-1), is a member of the C-C chemokine
family. It is expressed in most of the liver cell types such as hepatocytes, stellate
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cells and kupffer cells [80, 81] and is a potent chemotactic as well as
chemoattractant for monocytes [82, 83]. Previous studies have shown that CCL2
mRNA and protein expression is up regulated in chronic alcohol feeding in
rodents as well as in alcoholic hepatitis patients [80, 84-88]. Increased levels of
CCL2 recruited and activated monocytes /macrophages to the damaged tissue
site and stimulated pro-inflammatory cytokines production such as TNF-α, IL-1β
and IL-6 [89, 90]. Apart from activating macrophages, CCL2 plays a major role in
the development of hepatic steatosis and liver injury. Studies in primary
hepatocytes have demonstrated that CCL2 induces lipid accumulation during
tissue injury [91]. Moreover, a transgenic mouse overexpressing CCL2 in
adipose tissue showed increased hepatic triglycerides levels [92]. Interestingly,
CCL2 knockout mice were protected against alcoholic liver injury by the induction
of genes responsible for fatty acid oxidation and inhibition of pro-inflammatory
cytokines [93]. Since CCL2 regulates macrophage activation, pro-inflammatory
responses and hepatic steatosis in a chronic alcohol mice model,
pharmacological approaches to block CCL2 would be beneficial in treating early
stages of alcoholic liver disease such as steatohepatitis.
Intercellular adhesion molecule (ICAM-1) is expressed on kupffer cells,
hepatocyte and endothelial cells. ICAM-1 recruits leukocytes into inflammatory
sites by binding to its ligands LFA-1 or Mac-1, which are members of the
leukocyte integrin family. The activated leukocytes injure tissue by releasing
oxidants and proteases. Thus ICAM-1 could be involved in the pathogenesis of
inflammatory liver diseases such as ALD. ICAM-1 is associated with chronic
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alcohol exposure in patients with alcoholic liver disease [79]. Previous studies
done by Kono group have shown that ICAM-1 knockout mice were protected
from chronic ethanol induced liver injury by decreasing neutrophil infiltration and
hepatic steatosis [78]. Hence ICAM-1 plays a critical role in the recruitment of
neutrophils in alcohol-induced liver injury.
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Gut-Liver Axis in Alcoholic Liver Disease
Alcohol and gut barrier function
There is increasing evidence that demonstrates a critical pathogenic role
for the gut-liver axis in the development of ALD [94]. Alcohol has been shown to
change the composition of the microbiome as well as impair intestinal integrity
and barrier function [94, 95]. Integrity of intestinal barrier function is regulated, in
part, by the epithelial tight junction (TJ) complex composed of proteins such as
zonula occludens (ZO), occludin and claudins [96, 97]. The TJ complex
establishes intestinal barrier integrity by connecting the inter-epithelial cell
spaces and inhibiting the paracellular passage of microbes and microbial
products and other luminal contents [98-100]. An intact intestinal epithelial barrier
plays a major role in preventing intestinal invasion of luminal pathogens and
antigenic molecules and their subsequent migration to the liver and potentially
the systemic immune system. Accordingly, portal and systemic bacterial derived
lipopolysaccharide (LPS) levels are nearly undetectable in normal rats as well as
healthy people [76, 101, 102]. The clinical relevance of intestinal barrier
dysfunction has been recognized by its pathogenic association with the
development of ALD [103]. Direct evidence for decreased gut barrier function and
increased intestinal permeability was provided by the observations that oral
administration of LPS to alcohol-fed rats significantly increased systemic
endotoxin levels [104].
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Gut-derived endotoxemia and alcohol-induced liver injury
Besides the disruption of the gut barrier function, alcohol induced
alterations in the gut microbiota (dysbiosis) also can cause increased intestinal
endotoxin production, enhanced metabolism of ethanol into acetaldehyde leading
to further increase in intestinal permeability and translocation of bacteria and
bacterial products [105-112]. Recently our group had performed metagenomic
analyses to examine the effects of chronic alcohol feeding on the gut bacterial
microbiome by employing deep 16s rRNA gene sequencing using DNA isolated
from fecal samples [109]. The findings from this study showed that alcohol
feeding leads to significant shifts in the gut bacterial community with a marked
increase in the phylum Proteobacteria comprised of gram negative bacteria that
contain LPS in their cell wall and are the principal source of intestinal endotoxin
and systemic endotoxemia. Importantly, ethanol-mediated endotoxemia, along
with hepatic steatosis, inflammation and injury were markedly attenuated by
treatment with a probiotic Lactobacillus rhamnosus GG (LGG).
Due to its anatomical links to the gut, the liver is constantly exposed to
gut-derived bacterial products, and functions as a major filter organ and a first
line of defense. The frequency of systemic endotoxemia has been observed to
be significantly greater in patients with alcoholic cirrhosis than in non-alcoholic
cirrhotic subjects [76, 113]. Notably, plasma endotoxin levels are also
significantly elevated in alcohol consuming subjects without evidence of liver
disease [113]. These findings suggest a direct role for alcohol in inducing
systemic endotoxemia. Gut-derived endotoxin is a crucial mediator of liver injury
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and hepatic fibrosis/cirrhosis [114-116]. Importantly, gut-derived endotoxin,
seems to play a major role in the pathogenesis of ALD, as demonstrated by the
reduction of alcoholic liver injury following elimination of the Gram-negative
microbiota by antibiotics [117] and the sensitization to LPS-induced liver injury
following long-term ethanol exposure [118, 119].
Role of short chain fatty acids (SCFA) specifically butyrate in intestinal
health and diseases
The human gut harbors large and dynamic bacterial community consisting
of 300-500 different species of bacteria and the number of microbial cells within
the gut is 10 times larger than the eukaryotic cells in the human body [120, 121].
Short chain fatty acids are the processed by-products of the undigested long
chain polysaccharide by anaerobic bacteria present in the gut. The short chain
fatty acids found in the intestinal lumen includes acetate, propionate and butyrate
[122, 123] in the constant molar ratio of 60:25:15. Although butyrate is the least
abundant SCFA, it is important in maintaining the colonic mucosal health and
also serves as a main energy source for colonocytes [124]. In the colon grampositive anaerobic bacteria produce butyrate. Specifically, two groups of
butyrate-producing bacteria are Faecalibacterium prausnitzii. belonging to the
Clostridium leptum cluster, and Eubacterium rectale/Roseburiaspp. belonging to
the Clostridium coccoides cluster of firmicute bacteria [125]. During the
fermentation process decrease in the luminal pH is conducive for the growth of
butyrate-producing bacteria [126]. Previous studies from our lab have shown that
chronic alcohol administration alters the intestinal microbial environment by
increasing luminal pH leading to hepatic steatosis and inflammation and injury
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[109]. This could possibly explain the butyrate depletion in chronic alcohol
consumption.
Butyrate enters the cell by non-ionic diffusion, SCFA/HCO-3 exchange, and
active transport by SCFA transporters. Studies have shown that butyrate
exhibits a protective role by acting as a HDAC inhibitor [127]. Butyrate inhibits
majority of the HDACs except class II HDAC-6 and -10 and class III [127]. In
colon carcinoma cells, butyrate causes an imbalance in the histone acetylation
state affecting transcription of genes involved in cell cycle differentiation and
apoptosis and progression of cancer.[127-131]. Additionally, butyrate has been
shown to inhibit inflammatory responses through NFκB inhibition [132-134].
Butyrate also has a potential application in treating and preventing molecular
syndromes such as diet induced obesity and insulin resistance in humans [135].
Overall butyrate has a wide spectrum therapeutic potential in treating many
disease state as well as maintaining intestinal homeostasis by different
mechanisms the most common being butyrate acting as an HDAC inhibitor.
Limitations of Butyrate therapy
Although previous literature data has shown that butyrate has wide
spectrum possibilities as a therapeutic potential there are certain limitation to its
administration. Parental administration of butyrate has a very short plasma halflife due to which a sustained infusion of butyrate via i.v dosing is needed to
maintain the therapeutic concentration of butyrate in the plasma [136-139]. High
doses of i.v. butyrate solution can cause hypernatremia with narrow safety
window [140].
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Tributyrin as a best alternative for butyrate administration
Tributyrin (a prodrug of butyrate) is a triglyceride containing three butyrate
moieties esterified to glycerol. It is found in variety of foodstuff such as dairy
products [141]. Tributryin has better pharmacokinetic and pharmacodynamics
properties as compared to butyrate. The half-life of tributyrin is 40mins and it is
well tolerated when compared to i.v. butyrate solution [140, 142]. Oral
administration of Tributryin exhibits direct effects on liver by increasing the
hepato-portal concentration of butyrate [142, 143]. Recent research by Miyoshi
has shown that oral administration of tributyrin, upon digestion in the upper GI
tract, increases the butyrate concentration in the hepato-portal circulation and
attenuates LPS-induced liver injury and inflammatory reactions via suppression
of NF-kB activation.
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OVERALL HYPOTHESIS
We hypothesized that oral administration of tributyrin significantly attenuates
alcohol-induced hepatic steatosis, inflammation and injury in mice (Fig.1)

Fig.1
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MATERIALS AND METHODS
Animal Model
Eight-week-old male C57BL/6N mice were obtained from Harlan (Indianapolis,
IN). All mice were housed in a pathogen-free, temperature-controlled animal
facility accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care with 12 hour light/12 hour dark cycles. All experiments
were carried out according to the criteria outlined in the Guide for Care and Use
of Laboratory Animals and with approval of the University of Louisville Animal
Care and Use Committee. Animals were fed a modified Lieber-DeCarli liquid diet
containing alcohol (35% of total calories) and enriched in unsaturated fat (corn
oil) Research Diet, New Brunswick, NJ. Control liquid maltose-dextrin diets
provided 40% of energy from fat, 43% - from carbohydrate, 17% - from protein.
Initially, all mice were given the control liquid maltose dextrin diets ad libitum for
one week. Afterwards, mice were fed either the liquid ethanol diet or the control
liquid maltose-dextrin diet. Ethanol was gradually increased every 3-4 days from
11.2% to 35% of total calories (5.0% [vol/vol]). The mice were fed with the
alcohol diet (5% alcohol vol/vol) ad libitum. The control mice were pair-fed with
maltose-dextrin diets on an isocaloric basis. Tributyrin (Tb) purchased from
Sigma Aldrich (St. Louis MO) was orally gavaged at 2g/kg 5 days a week in
control mice as well as alcohol-fed mice.
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Materials
Tributyrin was purchased from Sigma (St. Louis MO)
Liver Histopathological Examination
For histological analysis, liver sections were fixed in 10% buffered formalin for 24
hours and embedded in paraffin. Tissue sections were stained with hematoxylineosin (H&E) and examined under light microscopy at 40× magnification.
Oil-Red-O Staining
To examine the amount of fat accumulation, the liver sections were stained with
Oil-Red-O. Frozen liver sections were washed in phosphate buffered saline twice
for 5 minutes. Oil-Red-O and 85% propylene glycol were added with agitation for
15 minutes, followed by washing in tap water.
Immunohistochemical staining
Mice liver sections were stained with F4/80+, and CAE staining, and tightjunction proteins such as anti-ZO-1 and Claudin antibody. Commercially
available antibody against and CPT-1 (Proteintech Group Inc., Chicago, IL) was
used for CPT-1 analysis. Assays were performed according to the
manufacturers’ protocols.
RNA Isolation and Real-Time PCR Analysis
Total RNA was isolated from the liver tissues using TRlzol®, according to
manufacturer's instructions. For real time PCR, the first strand cDNA was
synthesized using qScriptTM cDNA SuperMix (QuantaBiosciences, Inc,
Gaithersburg, MD) using 400ng of the total RNA. The RT conditions were 10
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mins at 25°C, 30mins at 48°C and 5 mins at 85°C. Real time PCR was performed
with an ABI prism 7500 sequence detection system and PerfeCtaTM SYBR
Green FastMixTM, Low ROX reagent (Quanta Biosciences, Inc.).Each sample
was run in duplicate reactions. Reverse transcriptase polymerase chain reaction
(RT-PCR) assays were used to assess mRNA levels of desired genes liver
tissues and in primary hepatocytes. The primers amplifying the genes examined
were designed in the lab and obtained from Intergrated DNA Technologies, Inc
(Coralville, IA). The parameter threshold cycle (Ct) was defined as the fraction
cycle number at which the fluorescence passed the threshold. The relative gene
expression was analyzed using the 2-AACt method by normalizing with β-actin
mRNA gene expression in all the experiments and is presented as fold change
over Untreated which is set at 1.
Assessment of Liver injury
Kits for biochemical analysis were purchased from the following: alanine
aminotransferase (ALT), Aspartate Aminotransferase (AST) and triacylglycerols
(TAG), Thermo Electron (Melbourne, Australia); nonesterified-fatty acid (NEFA),
Wako Chemical USA (Richmond, VA, USA). For liver TAG assay, hepatic tissue
(100 mg) was homogenized in 50 mM NaCl. The homogenate (500 µl) was
mixed with chloroform/methanol (2:1, 4 ml) and incubated overnight at room
temperature with gentle shaking. Homogenates were vortexed and centrifuged
for 5 min at 3000×g. The lower lipid phase was collected and concentrated by
vacuum. The lipid pellets were dissolved in 1% Triton X100 in phosphate-
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buffered saline, and hepatic TAG content was determined via enzymatic
colorimetric methods.
Blood Endotoxin Assay
Plasma endotoxin levels were measured with Limulus Amebocyte Lysate kit
(Lonza, Walkerville, MD) according to manufacturer’s instructions.
MPO activity assay
For hepatic myeloperoxidase activity (MPO), liver samples were homogenized
(10ug/200ul) in 200mM Nacl, 5mM EDTA, 10mM tris, 10% glycerin and
centrifuge at 1500g for 15mins. Activity was measured according to
manufacturer’s instuctions (Hycult Biotech Plymouth Meeting, PA) at 450nm
using a plate reader. Results are expressed as mg of MPO activity/ gram of
protein, as determined by Lowry Protein assay (Bio-Rad Hercules, CA)
Invitro studies
Rat primary hepatocytes were used in this study. Hepatocytes were isolated from
sprague dawley rats. Hepatocytes were treated with alcohol (50mM) with/without
NaB (2mM) which was pre-treated for half hour. At the end of 48hours, alcohol
and/or butyrate treated cells were treated with/without TNF-α (20ng/ml).
RAW 267.4 macrophages were also used in this study. They were treated with
LPS (10ng/ml) for 4 hours and pre-treated with/without NaB 2mM and
Triochostain A (TSA) (100ng/ml) for half hour. All cells were cultured in
Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 10 U/ml penicillin, and 10~g/ml streptomycin. Cells were
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maintained in an incubator at 37°C with humidified 5% CO2. Cells were plated
and incubated overnight before treatment, in all experiments.
Chromatin Immunoprecipitation (ChIP) and qChIP PCR analysis
The ChIP assay was conducted using the ChIP assay protocol established in the
lab. Briefly, 10 X 106 cells were crosslinked with 1% formaldehyde- 1 X-glycine
and lysed in lysis buffer containing protease inhibitor cocktail. Enzymatic
digestion of DNA was performed to produce chromatin fragments of 100–166 bp,
which were confirmed by running the chromatin on a 1% agarose gel. ChIP
antibodies directed against protein of choice were used for immunoprecipitation.
Anti-acetyl H3K9, anti-p300, anti-PGC-1, anti-Sp-1 and anti-RNA Polymerase II
were from EMDMillipore (MA, USA). The lysates were incubated overnight with
antibody, following which the antibody/protein complexes were
immunoprecipated using magnetic beads. Successive washes were performed
with low salt, high salt, LiCl and Tris EDTA (TE) wash buffers. After reverse
crosslinking and purification, pure DNA was eluted in elution buffer (1% SDS, 0.1
M NaHCO3). qChIP-PCR was performed using the ABI Prism 7500 Sequence
Detection System. ChIP- PCR primers designed for the regions of the CPT-1 and
PGC-1 promoters were used and their sequences are as follows:
Data was analyzed as Differential Occupancy Fold Change. ChIP-qPCR results
were calculated by ΔΔCt method (since all Ct values for a binding site are
determined from the same qPCR assay) where each ChIP DNA fractions Ct
value was normalized to the Input DNA fraction Ct value using ΔCt [normalized
ChIP] = (Ct [ChIP] - (Ct [Input] ). The difference between the normalized
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experimental sample (S2) and the control sample (S1) ChIP fraction Ct values
(second ΔΔCt) was determined using ΔΔCt [S2-S1] = ΔCt [S2: normalized ChIP]
- ΔCt [S1: normalized ChIP].
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mRNA PCR primer sequences
Rat
r.n_CPT-1a_F2
r.n_CPT-1a_R2

CTGCATGGAAGATGCTTTGA
GCCATGACATACTCCCACAA

r.n._Ccl2_F2
r.n._Ccl2_R2

GTCTCAGCCAGATGCAGTT
CTCTTGAGCTTGGTGACAAAT

Mouse
mm_CPT-1a_F1
mm_CPT-1a_R1

GCTGCACTCCTGGAAGAAGA
GGAGGGGTCCACTTTGGTAT

mmCcl2_F
mmCcl2_R

GGCTCAGCCAGATGCAGT
TGAGCTTGGTGACAAAAACTACAG

mmCxcl2_F3
mmCxcl2_R3

GCGCCCAGACAGAAGTCATA
TCCAGGTCAGTTAGCCTTGC

mm_Icam1_F2
mm_Icam1_R2

CGCTGTGCTTTGAGAACTGT
TGAGGTCCTTGCCTACTTGC

m_Actb_F2
m_Actb_R2

CAGCTGAGAGGGAAATCGTG
CTCCAGGGAGGAAGAGGATG

m_Tnf_F2
rod_Tnf_R2

GTGATCGGTCCCCAAAGG
GGTGGTTTGCTACGACGTG
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ChIP PCR Primers
CPT-1 TRE For
CPT-1 TRE Rev

GGTGACGTTGGCTGAGCAA
TGAGCCCCTGTACACGTTTTG

r.n.CPT-1_Chp2_F
r.n.CPT-1_Chp2_R

ATGGGCATGGCTTTAATGAG
GGCTAGGACCCGAGCTTGT

r_n_CPT-1GCTSs_F4
r_n_CPT-1_GCTSs_R4

AGCCTCGCCCGCCCCTGCTC
CAGCGCTGCCCTCCCGGTGTC

mm_Ppargc1a_TSS_F4 TGACAGCCCAGCCTACTTTT
mm_Ppargc1a_TSS_R4 CACACAGCACACACTCATGC

Statistical Analysis
Data are presented as means± SD for the indicated number of independently
performed experiments. Student's t-test and one-way ANOVA with Bonferroni
multiple comparison test were used for the determination of statistical
significance. P<0.05 was considered significant.
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RESULTS
Tributyrin protects alcohol mediated down-regulation of tight-junction
proteins and resultant intestinal permeability and systemic endotoxemia
Intestinal tight junctions (TJ) play a major role in maintaining the barrier integrity,
thus preventing release of toxins such as endotoxin into the systemic circulation.
ZO-1 and Occludin are tight junction proteins, critical for the gut integrity and
barrier function. Initially we investigated the effect of tributyrin on TJ proteins in
chronic alcohol fed animals. Mice were orally administered tributyrin at a
concentration of 2g/kg with or without 5% Alcohol via Lieber DeCarli diet for 4
weeks. The expression of TJ proteins specifically ZO-1 and Occludin was
examined by immunostaining the intestinal ileum sections (Fig. 2). Similar to
other studies, we also observed that chronic alcohol administration decreased
ZO-1 and Occludin protein expression in the ileum compared to pair-fed mice.
Notably, tributyrin administration prevented the chronic alcohol-induced loss of
ZO-1 and occludin proteins. Tributyrin alone group showed no change in
expression of these proteins. This data showed that tributyrin administration can
restore the barrier integrity by preventing the alcohol-induced decrease in tight
junction proteins. Hence, we next examined the effect of tributyrin on barrier
function/permeability by measuring the systemic endotoxin levels. The data
showed that chronic alcohol consumption caused increase in systemic endotoxin
levels. Importantly, tributyrin treatment significantly attenuated alcohol-induced
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increase in serum endotoxin levels (Fig.3). Overall, these data showed that
tributyrin protects the gut barrier function by restoring tight-junction proteins and
resultant decrease in intestinal permeability and systemic endotoxemia, observed
in chronic alcohol fed animals.
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Fig.(2): Effect of tributyrin administration on intestinal tight junction protein
expression: Mice were pair-fed with either control diet or ethanol (5%v/v)
containing diet along with tributyrin (2g/kg) orally gavaged. Occludin (green)
and ZO-1 (red) were visualized by immunohistochemistry in sections of colon
frozen in OCT. Nuclei were counterstained with DAPI (blue). All images were
acquired using a 409 objective.
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Fig. (3): Effect of tributyin administration on alcohol–induced endotoxemia:
Mice were pair-fed with either control diet (PF) or ethanol (AF) (5%v/v)
containing diet along with tributyrin (Tb)(2g/kg) orally gavaged. Serum
endotoxin levels assessed by biochemical assay were significantly elevated in
alcohol treated mice and attenuated by tributyrin administration. Data are
expressed as mean ±SEM, n = 4 to 6 animals/per group. a = compared to
control, b = compared to alcohol.
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Tributyrin attenuates alcohol-induced hepatic steatosis
Oral administration of tributyrin has been shown to increase concentration of
butyrate in the portal vein and prevent lipopolysaccharide-induced liver injury in
rats (Miyoshi et al). Since our earlier data showed that tributyrin decreases
endotoxemia in alcohol fed mice, we examined its effects on hepatic steatosis
which is a primary pathological consequence of chronic ethanol consumption.
Histological analysis of the livers as shown by H&E (Fig. 4) and Oil red O (Fig.5)
staining revealed increase steatosis in livers of chronic alcohol fed mice.
Interestingly, alcohol intake-induced fat accumulation was significantly attenuated
by the tributyrin treatment. Effect of tributyrin on hepatic steatosis was further
confirmed by hepatic triglyceride (Fig.6) and Non-esterified free fatty acids
(NEFA) analysis (Fig.6). As expected, hepatic triglycerides and free fatty acids
were increased in alcohol-fed mice compared to pair fed animals However, in
correspondence with the immunohistochemistry of the livers, tributyrin treatment
significantly blunted alcohol-induced hepatic triglycerides as well as free fatty
acids. These results provides compelling evidence that oral administration of
tributyrin can prevent development of alcoholic fatty liver in mice.
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Control

Tributyrin

Alcohol

Alcohol+Tributyrin

Fig.(4): Effect of Tributyrin administration on alcohol-induced fatty liver. Mice
were pair-fed with either control diet or ethanol (5%v/v) containing diet along
with tributyrin (2g/kg) orally gavaged. Representative micrographs are shown
depicting H&E staining (magnification 20X) of liver sections revealing fat
accumulation in the liver of alcohol fed mice
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Fig.(5): Effect of Tributyrin administration on alcohol-induced fatty liver. Mice
were pair-fed with either control diet or ethanol (5%v/v) containing diet along
with tributyrin (2g/kg) orally gavaged. Representative micrographs are shown
depicting Oil-Red O staining (magnification 20X) of liver sections revealing fat
accumulation in the liver of alcohol fed mice
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Fig.(6): Effect of tributyrin administration on alcohol-induced hepatic steatosis
as assessed by hepatic free fatty acids and triglyceride : Mice were pair-fed
with either control diet (PF) or ethanol (AF) (5%v/v) containing diet along with
tributyrin (Tb)(2g/kg) orally gavaged. Data are expressed as mean ±SEM, n =
4 to 6 animals/per group. a = compared to control, b = compared to alcohol.
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Tributyrin administration prevents the decrease of CPT-1 gene expression
in alcohol-fed mice
We and others have earlier demonstrated that alcohol-mediated down-regulation
of CPT-1 plays a major role in the development of micro as well as macrovesicular steatosis [17-19, 144, 145]. Biochemically, CPT-1 is a rate-limiting
enzyme in mitochondrial free fatty acid β-oxidation. Hence, to explore the
potential mechanism through which tributyrin attenuates alcohol-induced hepatic
steatosis, we examined CPT-1 mRNA levels by real time PCR from animal livers.
Similar to our binge ethanol model, chronic ethanol feeding also significantly
suppressed hepatic CPT-1 mRNA expression (Fig. 7) and led to down regulation
in its protein expression as shown by the anti-CPT-1 staining in liver sections
(Fig.8). Interestingly, tributyrin administration alone showed the highest
expression at the mRNA level as compared to pair-fed control and alcohol fed
animals. These data suggest that tributyrin administration increases β-oxidation
by increasing hepatic CPT-1 gene expression and thus mitigates alcohol-induced
hepatic steatosis.
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Fig.(7): Effect of tributyrin administration on alcohol induced down-regulation
of CPT-1 gene expression: CPT-1 mRNA levels were significantly downregulated in alcohol fed mice and was further restored and increased by
tributyrin treatment. CPT-1 mRNA levels were analyzed by RT-qPCR and
normalized to β -actin mRNA. Data are expressed as mean ±SEM, n = 5
animals/per group. a = compared to control, b = compared to alcohol.
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Pair-Fed

Tributyrin

Alcohol

Alcohol+Tributyrin

Fig.(8): Effect of Tributyrin administration on hepatic CPT-1 protein
expression in mice liver. Mice were pair-fed with either control diet or ethanol
(5%v/v) containing diet along with tributyrin (2g/kg) orally gavaged.
Immunohistochemical staining with anti-CPT-1 antibody (magnification 20X)
demonstrated that hepatic CPT-1 protein levels (staining) were decreased in
the liver of alcohol-fed mice and restored by tributyrin administration.

41

Evaluation of Alcohol and Butyrate Mediated Transcriptional Regulation of
CPT-1 Gene Expression
To determine the mechanisms underlying the chronic alcohol consumption
mediated suppression of CPT-1 gene expression and the therapeutic effects of
butyrate, we performed in vitro analysis using freshly isolated primary
hepatocytes. As mentioned earlier orally administered tributyrin has shown to
increase butyrate levels in the hepato-portal circulation. Hence butyrate was
used in all the in vitro studies. Primary hepatocytes were either left untreated
(UT) or treated with 50mM ethanol (for 48hrs) with or without sodium butyrate
(NaB; 2mM). NaB was added 30 min prior to ethanol treatment. The data
obtained from the primary hepatocytes confirmed our in vivo findings on CPT-1
gene expression. Indeed, NaB pretreatment not only prevented the alcoholinduced decrease but further enhanced CPT-1 mRNA expression (Fig. 9).
Effect of Alcohol and Butyrate on PGC-1 - a key co-activator of CPT-1 gene
expression
PGC-1 is an essential transcriptional co-activator of hepatic CPT-1 gene
expression and is known to be downregulated by alcohol [34, 42, 49]. 48 hours of
alcohol significantly suppressed PGC-1 gene expression, whereas butyrate pretreatment not only reversed but also robustly induced PGC-1 gene expression in
primary hepatocytes. (Fig.10).
Biological effects of butyrate are mediated by its ability to primarily
function as a Class I/II HDAC inhibitor which can increase histone acetylation
and activate gene expression [146]. Hence, to address the butyrate effect of
enhancing PGC-1 mRNA expression, promoter histone acetylation was
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assessed. Specifically, histone acetylation in the promoter region encompassing
the cAMP response element (CRE) that binds CREB, a known transcription
factor for PGC-1 expression was examined (Fig.11). Chromatin was prepared
from the rat primary hepatocytes treated with alcohol 50mM and with/without
pretreatment with NaB 2mM as well as from NaB alone for 12hours. ChIP
analysis was performed using an Ab that selectively recognizes H3K9Ac.
Commensurate with its effect on PGC-1 mRNA, butyrate was observed to
prevent alcohol induced decrease in promoter H3K9Ac levels and in fact
increased the levels over base line (Fig.12).
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Fig.(9): Effect of butyrate on alcohol mediated down-regulation of CPT-1 gene
expression. Primary hepatocytes were untreated (UT) or treated with 50mM
alcohol (A) for 48h. Cells were pretreated with sodium butyrate for 30 min prior
to alcohol. CPT-1 mRNA levels were analyzed by RT-qPCR and normalized to
β-actin mRNA. Data are expressed as mean ±SEM, n = 3. a = compared to
untreated, b = compared to alcohol.

44

20

b

10

2

a

1

aB
N

N
aB
lc
oh
ol
+

A

A

U

lc
oh
ol

0
T

Fold over Untreated
PGC-1

PGC-1 mRNA

Fig.(10): Effect of butyrate on alcohol mediated down-regulation of PGC-1 gene
expression Primary hepatocytes were untreated (UT) or treated with 50mM
alcohol (A) for 48h. Cells were pretreated with sodium butyrate for 30 min. PGC-1
mRNA levels were analyzed by RT-qPCR and normalized to β-actin mRNA. Data
are expressed as mean ±SEM, n = 3. a = compared to untreated, b = compared to
alcohol.
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Transcription start site (TSS)

Schematic of PGC-1 promoter

Fig.(11) PGC-1 promoter schematic. Location of ChIP PCR primer pair for
analysis of epigenetic modifications is shown in the schematic with respect to
the +1 start site REFSEQ NM_000639.1
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Fig.(12) H3K9Ac enhancement at PGC-1 promoter by butyrate: Primary
hepatocytes were untreated (UT) or treated with 50mM alcohol for 12h.
Sodium butyrate was pretreated for 30 min. Chromatin fragments were
immunoprecipitated with H3K9Ac antibody and ChIP-qPCR was performed
using primer pair specific for TSS site on PGC-1 promoter. A representative
PCR data is shown. Non-immunoprecipitated chromatin was used as input.
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DR-1
site

TSS
site
SP-1
site

Schematic of CPT-1 promoter
promoter
Fig.(13) CPT-1 promoter schematic: Locations of key transcriptionally active regions
and ChIP PCR primer pairs for analysis of epigenetic modifications are denoted. The
coordinate locations shown are with respect to the +1 start site REFSEQ
NM_000639.1
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Effect of Alcohol and Butyrate on CPT-1 Transcriptional Mechanisms
Effect on the recruitment of co-activators PGC-1and p300
PGC-1 is a key transcriptional coactivator of CPT-1 gene expression. As a
coactivator, PGC-1 can recruit and facilitate interactions with other coactivators
such histone acetyl transferases (HATS; e.g. SRC-1, p300) that can induce
chromatin remodeling via histone acetylation [147, 148]. Hence, in correlation
with the observed CPT-1 and PGC-1 mRNA expression we examined the effect
of alcohol and butyrate on PGC-1 and p300 protein recruitment to the
transcriptionally relevant CPT-1 promoter regions denoted as DR-1 site and SP-1
site (Fig. 13) Chromatin from alcohol and NaB treated hepatocytes was obtained
as mentioned above and ChIP analysis was performed using PGC-1 specific
antibodies. Relative to CPT-1 mRNA expression, alcohol decreased PGC-1
binding which was prevented by NaB (Fig.14). Following PGC-1, recruitment of
HAT - p300 to the relevant CPT-1 promoter region was evaluated. Proportional to
PGC-1 recruitment and its coactivator function, alcohols diminishing effect on
p300 binding was counteracted by NaB resulting in an increase in its binding
(Fig.15).
Subsequent to examining the effects of alcohol and butyrate on PGC-1 and
p300 recruitment, we examined their effect on promoter histone modifications as
pertinent epigenetic mechanisms dictating CPT-1 transcription. Promoter
histone modifications were examined by ChIP qPCR analysis [149] using PCR
primer sets for region that overlaps the transcription state site (TSS site).
Specifically, the status of histone H3 lysine 9 acetylation (H3K9Ac) was assessed
which plays a key role in the transcriptional activation of gene expression.
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Chromatin from primary hepatocytes treated with ethanol and NaB was
evaluated by ChIP analysis by using an Ab that selectively recognizes H3K9Ac.
Commensurate with the observed decrease in CPT-1 mRNA levels as well as
PGC-1 and p300 binding, ethanol treatment led to a decrease in the promoter
H3K9Ac levels indicative of a transcriptionally repressive chromatin state. In
comparison, NaB pre-treatment not only inhibited the ethanol induced decrease,
but also increased H3K9Ac levels over base-line. Interestingly, NaB alone
markedly increased CPT-1 promoter H3K9Ac levels and induced CPT-1
transcription (Fig.16). These data suggest that the protective effect of NaB is
significantly mediated through its ability to function as an HDAC inhibitor.
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Fig: (14) Increase in PGC-1 binding at the CPT-1 promoter by butyrate: Primary
hepatocytes were untreated (UT) or treated with 50mM alcohol for 12h. Sodium
butyrate was pretreated for 30 min prior to alcohol. Chromatin fragments were
immunoprecipitated with PGC-1 antibody and ChIP-qPCR was performed using
primer pair specific for DR-1 site on CPT-1 promoter. Representative PCR data
is shown. Non-immunoprecipitated chromatin was used as input to normalize
the data.
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Fig.(15) Increase in p300 recriuitment by PGC-1 at the CPT-1 promoter by
butyrate: Primary hepatocytes were untreated (UT) or treated with 50mM
alcohol for 12h. Sodium butyrate was pretreated for 30 min. Chromatin
fragments were immunoprecipitated with p300 antibody and ChIP-qPCR was
performed using primer pairs specific for DR-1 site on CPT-1 promoter.
Representative PCR data is shown. Non-immunoprecipitated chromatin was
used as input to normalize the data.
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Fig.(16) Increase in H3K9Ac levels at the TSS site of the CPT-1 promoter by
butyrate: Primary hepatocytes were untreated (UT) or treated with 50mM
alcohol for 12h. Sodium butyrate was pretreated for 30 min prior to alcohol.
Chromatin fragments were immunoprecipitated with H3K9Ac antibody and
ChIP-qPCR was performed using primer pairs specific for TSS site and SP-1
site on CPT-1 promoter. A representative PCR data is shown. Nonimmunoprecipitated chromatin was used as input.
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Effect on CPT-1 transcription pre-initiation complex
Earlier studies have demonstrated that CPT-1 is a TATA-less gene and
transcription factor Sp1 is significantly involved in the regulation of basal as well
as inducible transcriptional activation of CPT-1 gene expression [43, 44]. Hence,
having determined the impact of alcohol and butyrate on the recruitment of coactivators and promoter histone acetylation affecting CPT-1 mRNA expression,
we then examined the effects on Sp1 and RNA Pol II binding that constitutes the
relevant components of the CPT-1 transcription pre-initiation complex.
Chromatin from primary hepatocytes treated with ethanol and NaB was
evaluated by ChIP analysis by using antibodies that selectively recognize Sp1
and RNA Pol II. Sp1 binding was examined at Sp1 site and RNA PolII binding
was examined at the TSS site (Fig.13). In correlation with the decrease in CPT-1
mRNA expression, alcohol induced a disruption of the transcriptional preinitiation complex as indicated by the decline in transcription factor - Sp1 binding
and recruitment of RNA Pol II at the CPT-1 promoter (Fig.17, 19). Importantly,
butyrate in correlation with an increase in CPT-1 promoter histone acetylation
indicative of an increase in the transcriptionally active state, led to an increase in
Sp1 binding and RNA Pol II recruitment and recommencement of the formation
of the transcriptional pre-initiation complex. Moreover Sp1 is known to promote
transcription by interacting and recruiting p300 [150]. Indeed, a butyrate
mediated increase in p300 binding to the Sp1 region of the CPT-1 promoter was
also observed in alcohol treated hepatocytes (Fig.18).
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These data strongly suggest that p300 recruitment via Sp1, besides PGC-1,
could have also contributed to the net dynamic increase in CPT-1 promoter
histone acetylation and transcriptional activation.
Overall, oral administration of tributyrin significantly protects gut barrier
function and attenuates chronic alcohol-induced hepatic steatosis. Specifically,
tributyrin induces transcriptionally permissive chromatin modifications at the
CPT-1 promoter and thus improves CPT-1 gene expression and β-oxidation in
the chronic alcohol fed animals.
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Fig.(17) Increase in Sp-1 binding at the Sp-1 site on the CPT-1 promoter by
butyrate: Increase in PGC-1 binding at the CPT-1 promoter by butyrate Primary
hepatocytes were untreated (UT) or treated with 50mM alcohol for 12h. Sodium
butyrate was pretreated for 30 min. Chromatin fragments were
immunoprecipitated with SP-1 antibody and ChIP-qPCR was performed using
primer pair specific for SP-1 site on CPT-1 promoter. Representative PCR data
is shown. Non-immunoprecipitated chromatin was used as input to normalize
the data.
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Fig.(18) Increase in p300 recruitment by SP-1 at the SP-1 site on the CPT-1
promoter: Primary hepatocytes were untreated (UT) or treated with 50mM
alcohol for 12h. Sodium butyrate was pretreated for 30 min. Chromatin
fragments were immunoprecipitated with p300 antibody and ChIP-qPCR was
performed using primer pairs specific for SP-1 site on CPT-1 promoter.
Representative PCR data is shown. Non-immunoprecipitated chromatin was
used as input to normalize the data.
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Fig.(19) Increase in RNA pol II at the TSS site on the CPT-1 promoter: Primary
hepatocytes were untreated (UT) or treated with 50mM alcohol (A) for 12h.
Sodium butyrate was pretreated for 30 min. Chromatin fragments were
immunoprecipitated with RNA-Pol II antibody and ChIP-qPCR was performed
using primer pair specific for TSS site on CPT-1 promoter. Representative PCR
data is shown. Non-immunoprecipitated chromatin was used as input to
normalize the data.
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Tributyrin administration protects from alcohol-induced hepatic
inflammation and injury
Studies have shown that 10-30% heavy drinkers progresses from hepatic
steatosis to hepatic inflammation and injury. Activation of innate immune
response either by kupffer cells which are resident macrophages or infiltrating
macrophages and resultant pro-inflammatory cytokine production such as TNF-α,
IL-8, IL-1β have been well documented in alcoholic liver disease. Since tributyrin
showed protection against alcohol induced steatosis we next investigated its
impact on hepatic inflammation and injury.
Tributyrin inhibits the alcohol-mediated macrophage activation and proinflammatory cytokine -TNF-α expression
The effect of tributyrin on macrophage activation was evaluated by
immunohistochemistry for F4/80-positive macrophages in the liver tissue
(Fig.20). Data showed that there are more F4/80 positive macrophages as seen
by brown stained cells in alcohol fed animals but that number was markedly less
in the tributyrin and alcohol together treated mice. Additionally, the macrophage
activation was further confirmed by measuring pro-inflammatory cytokine, tumor
necrosis factor-α (TNF-α) production (Fig.21). In accordance with macrophage
activation, the TNF-α mRNA levels were high at 2 weeks alcohol feeding but
were significantly decreased in mice that received tributyrin administration along
with alcohol feeding. Tributyrin alone did show marginal increase in TNF-α
mRNA levels but difference was not significant as compared to pair-fed controls.
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Butyrate down-regulated LPS inducible TNF-a gene expression in RAW
cells
Since increase TNF-α expression was seen in two week alcohol fed animals and
Aldred et al. have shown that after chronic alcohol consumption,
macrophages/Kupffer cells demonstrate enhanced LPS-stimulated TNF-α
production[151]. We next examine the effect of butyrate on LPS inducible TNF-α
gene expression in RAW cells (Fig.22). The data showed that LPS (100ng/ml)
treatment caused robust upregulation (~ 20 fold) in the TNF-α mRNA levels as
compared to untreated cells; however the Na-butyrate (1mM) pretreatment
inhibited LPS-stimulated TNF-α gene expression. These data further support the
mechanistic role of tributyrin in the down-regulation of alcohol induced hepatic
inflammation.
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Fig.(20) Effect of tributyrin administration on F4/80 positive cells in mice
chronically fed alcohol for 2 weeks. Representative micrographs are shown
depicting F4/80 staining of liver sections revealed increased macropage
infiltration in liver of alcohol fed mice which is attenuated in tributyrin treated
mice
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Fig.(21) Chronic alcohol-induced TNF-α gene expression: Alcohol significantly
induced TNF-α gene expression which was attenuated by tributyrin treatment.
TNF-α mRNA levels were analyzed by RT-qPCR and normalized to β -actin
mRNA. Data are expressed as mean ±SEM, n = 5 animals/per group.
a = compared to control and b = alcohol.
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Fig.(22) LPS inducible TNF-α gene expression in RAW 264.7: LPS (100ng/ml)
inducible TNF-α gene expression was attenuated by butyrate 2mM tributyrin
treatment. TNF-α mRNA levels were analyzed by RT-qPCR and normalized to
β-actin mRNA. Data are expressed as mean ±SEM, n =3. a = UT and b = LPS
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Tributyrin administration significantly attenuates chronic alcohol-induced
MCP-1 (CCL-2) gene expression in mice and rat hepatocytes
MCP-1 upregulation plays a critical pathogenic role in the progression of alcoholinduced hepatic inflammation and injury in C57BL/6 mice as well as alcoholic
hepatitis patients [93]. Hence in our animal model we investigated the effect of
tributyrin/butyrate on the alcohol-induced regulation CCL-2 gene expression. In
this model C57BL/6 mice were fed the Leiber-Decarli diet or its isocaloric control
(Pair-fed PF) to determine the expression of CCL-2 in the whole liver. Two weeks
of chronic alcohol feeding significantly induced (~3 fold) CCL-2 gene expression
in the liver. This CCL-2 induction was further upregulated (~7 fold) at the end 7
weeks. Tributyrin co-administration markedly suppressed the induction of
alcohol-induced hepatic CCL-2 at 2 as well as 7 weeks of alcohol feeding to
baseline pair-fed level (Fig.23). To isolate the role of hepatocytes in the alcoholinduced CCL-2 expression, rat primary hepatocytes were treated with alcohol
(50mM) for 48hrs and TNF-α (20ng/ml) for 4 hrs. with/without pretreatment of
butyrate (2mM, 30min). TNF-α exposure alone induced ~10 fold up-regulation in
CCL-2 gene expression over untreated. Moreover, alcohol further primed the
cells to TNF-α induced CCL-2 expression upto~35 fold as compared to untreated
cells. Pre-treatment with NaB significantly attenuated CCL-2 gene expression
induced in response to TNF-a as well as combination of alcohol and TNF-α
treatment (Fig. 24). These data indicates that tributyrin administration
significantly down-regulates chronic-alcohol induced CCL-2 gene expression in
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the whole liver as well as in CCL-2 producing hepatocytes leading to decrease in
alcohol-mediated hepatic inflammation and injury.
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Fig.(23)Chronic alcohol induced CCL2 gene expression in alcohol fed mice:
CCL2 mRNA levels were up-regulated in alcohol fed mice livers and was
attenuated by tributyrin treatment. CCL2 mRNA levels were analyzed by RTqPCR and normalized to β-actin mRNA. Data are expressed as mean ±SEM,
n = 5 animals/per group. p value a = when compared to control and b = when
compared to alcohol.
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Fig.(24) Chronic alcohol induced CCL2 gene expression in rat primary
hepatocytes: Hepatocytes were treated with alcohol 50mM for 48hrs and TNFα (20ng/ml) for 4hrs with/without Sodium butyrate (NaB). CCL2 mRNA levels
were analyzed by RT-qPCR and normalized to β-actin mRNA. Data are
expressed as mean ±SEM, n = 3. p value a when compared to control; b when
compared to TNF-α; d when compared to alcohol and e when compared to
Alcohol +TNF-α.
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Tributyrin administration significantly attenuates chronic alcohol-induced
CXCL-2 (MIP-2) gene expression in mice
One of the key pro-inflammatory cytokines involved in modulating the
inflammatory response is the CXC chemokine interleukin-8 (IL-8), which
functions as a critical chemoattractant and activator for neutrophils, basophils,
and T cells. Sustained consumption of ethanol was shown to be associated with
elevated serum as well as hepatic MIP-2 [87, 152]. Hence we examined the
expression of CXCL2 in the alcohol-fed mice with/without tributyrin coadministration. Two weeks of alcohol-feeding did not induce CXCL2 gene
expression in the liver although a trend was observed. However, sustained
alcohol consumption upto 7 weeks significantly induced CXCL-2 gene
expression. This alcohol-induced CXCL2 gene expression was significantly
suppressed by tributyrin administration suggesting that tributyrin attenuated
hepatic inflammation caused due to CXCL2 cytokine production (Fig.25).
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Fig.(25) Chronic alcohol induced chemokine CXCL2 gene expression: CXCL2
mRNA levels were up-regulated in alcohol fed mice and were attenuated by
tributyrin treatment. CXCL2 mRNA levels were analyzed by RT-qPCR and
normalized to β-actin mRNA. Data are expressed as mean ±SEM, n = 5
animals/per group. p value a = control and b = when compared to alcohol.
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Tributryin administration significantly down-regulates adhesion molecule
(ICAM-1) in alcohol-fed mice
It has been shown ICAM-1 plays an important role in alcohol-induced liver
injury by facilitating adhesion of leukocytes such as neutrophils [78]. In our
chronic alcohol feeding model ICAM-1 mRNA expression was significantly
induced compared to pair-fed controls. Tributyrin co-administration significantly
decreased alcohol-induced ICAM-1 gene expression in C57BL/6 mice
(Fig. 26).
Tributyrin administration decreases neutrophil infiltration in alcohol-fed
mice
Neutrophil infiltration is a hallmark of hepatic inflammation. The above data show
that expression of MCP-1 and MIP-2, which are potent chemoattractants for
monocytes and/or neutrophils, was unregulated after chronic-alcohol feeding.
Therefore, we stained the liver with CAE to scan neutrophils infiltration. As
expected, seven weeks of alcohol exposure increased hepatic neutrophils.
However, tributyrin administration suppressed neutrophil infiltration as seen by
decreased CAE staining (Fig. 27). Neutrophil infiltration was further confirmed by
MPO activity assay. MPO activity was significantly increased in alcohol-fed mice
at 7 weeks of alcohol feeding (Fig. 28). Tributyrin co-administration significantly
reduced MPO activity in the liver. This data indicate that tributyrin administration
significantly reduces hepatic inflammation in alcohol-fed mice.
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Fig.(26) Chronic alcohol-induced chemokine ICAM-1 gene expression: ICAM-1
mRNA levels were up-regulated in alcohol fed mice and was attenuated by
tributyrin treatment. ICAM-1 mRNA levels were analyzed by RT-qPCR and
normalized to β-actin mRNA. Data are expressed as mean ±SEM, n = 5
animals/per group. a = control and b = when compared to alcohol.
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Fig.(27) Effect of tributyrin administration on liver histopathology in mice
chronically fed alcohol for 7 weeks. Representative micrographs are shown
depicting CAE staining of the liver sections revealing neutrophil infiltration in the
alcohol fed mice livers
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Fig.(28) Hepatic MPO activity in response to alcohol and tributyrin: Hepatic
MPO activity in mice was significantly elevated in 7 weeks of alcohol feeding
and attenuated by tributyrin treatment. Data are expressed as mean ±SEM,
n = 4 to 6 animals/per group. a = compared to control, b = compared to alcohol.
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Administration of Tributyrin attenuated Aspartate Transaminase (AST) and
Alanine Transaminase (ALT) in alcohol-fed mice
Serum ALT and AST levels are the hallmark of liver injury. It has been well
documented that chronic as well as binge alcohol consumption increases AST
and ALT levels in the blood indicating liver injury. Hepatic steatosis and
inflammation predisposes the liver to cause injury. Hence we measured serum
AST and ALT levels in these mice and as expected AST and ALT levels were
significantly elevated compared to pair-fed control mice. Co-administration of
tributyrin along with alcohol markedly suppressed AST and ALT in mice. This
data demonstrates that along with markedly reducing alcohol-induced
inflammatory responses in the liver, tributyrin administration attenuated
hepatocyte damage and liver injury in chronic alcohol fed mice (Fig. 29).
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Fig.(29) Effect of tributyrin administration on liver injury in mice chronically fed
alcohol for 7 weeks: ALT and AST activity was significantly elevated in 7 weeks
of alcohol feeding mice and markedly attenuated by tributyrin treatment. Data are
expressed as mean ±SEM, n = 4 to 6 animals/per group. a = compared to
control, b = compared to alcohol.
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DISCUSSION
Understanding the pathophysiology and the mechanisms of chronic
alcohol-mediated steatosis and steatohepatitis has led to the advancement of
new preventive and beneficial strategies in treating alcoholic liver disease.
Recent studies have shown that alcohol decreases short-chain fatty acids
(SCFAs) [153]. SCFAs, predominantly acetate, propionate and butyrate, are the
end-products of anaerobic bacterial fermentation of carbohydrates in the colon.
SCFAs, especially butyrate, play important roles in the biology of colonocytes, by
acting as the principal energy source and maintaining the integrity of the
intestinal environment [122, 154]. Tributyrin is a butyrate prodrug, and oral
administration of tributyrin has been shown to increase butyrate concentration in
the hepato-portal circulation [155]. Hence the present study examined the role of
tributyrin supplementation in the prevention of alcohol-induced hepatic steatosis,
inflammation and injury.
Alcohol consumption causes gut microbial dysbiosis and affect intestinal
tight junction protein expression leading to systemic endotoxemia [156]. Since
tributyrin is metabolized to butyrate by the intestinal bacteria and pancreatic
lipases and has been shown to have protective effects on gut barrier integrity we
initially investigated the role of orally administered tributyrin on intestinal ileum
tight junction. In accordance to the previous studies [156], tributyrin
supplementation prevented the loss of alcohol-induced TJ proteins. Previous
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studies have shown that butyrate treatment improves TJ protein expression by
AMPK [157]. Chronic alcohol exposure can decrease the phosphorylation of
AMPK leading to its inactivation. Butyrate could be increasing phosphorylation of
AMPK during chronic alcohol exposure. This could be a possible mechanism by
which butyrate improves the alcohol-mediated suppression of TJ-proteins. In
accordance to the literature, alcohol increased systemic endotoxin and was
significantly attenuated by tributyrin co-administration.
Hepatic steatosis predisposes the liver to second hits and injuries allowing the
progression to severe forms of disease. Alterations in the gut-liver axis are
known to drive liver damage. Importantly, it has been shown that oral
administration of tributyrin increases the concentration of butyrate in the
hepatoportal vein exerting its beneficial effects on the liver [155]. Since we
observed tributyrin protection on gut associated changes, we further examined
the effect of tributyrin on liver. Immunohistochemical staining and biochemical
parameters of hepatic steatosis such as hepatic triglycerides and free fatty acids
were significantly reduced by tributyrin. Hepatic triglyceride accumulation and
steatosis can occur as a consequence of increased fatty acid synthesis as well
as decreased β-oxidation of fatty acids. Recent studies have shown that alcohol
consumption affects both these pathways in hepatic steatosis [7, 158, 159].
Previous studies from our lab have shown that a decrease in CPT-1 plays a
critical role in binge alcohol-induced hepatic steatosis [17, 145]. Notably, in the
present study Tributyrin/butyrate treatment not only reversed CPT-1 gene
expression in chronic alcohol-fed mice and primary hepatocytes but also
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augmented its baseline expression. Because CPT-1 catalyzes a rate limiting step
in mitochondrial free fatty acid β-oxidation, upregulation by tributyrin/butyrate is a
significant contributory factor in preventing the development of chronic alcoholinduced liver steatosis. Hence we further investigated the mechanisms
underlying the therapeutic effects of butyrate on CPT-1 gene expression by
alcohol.
PGC-1 is shown to be a critical co-activator in regulating CPT-1 gene
expression [160]. Importantly, it has been reported that PGC-1deficiency leads to
the development of hepatic steatosis whereas overexpression of PGC-1 alone is
sufficient to induce CPT-1 transcription. Butyrate treatment robustly induced
PGC-1 gene expression in the alcohol treated cells indicating that increase in
PGC-1 could be a major player in tributyrin mediated up-regulation of CPT-1. In
the context of CPT- 1 transcriptional activation, PGC-1 acts as a co-activator and
interacts with transcription factors such as PPAR-α, HNF4α increasing promoter
histone acetylation [42][35][34]. Interestingly, alcohol treatment was observed to
decrease PGC-1 recruitment only at the HNF4α binding region (DR-1 site)
(fig.15) with minimal to no effect at the PPAR-α binding site (PPRE site) (data not
shown). These data indicate that butyrate mediated transcriptional activation of
CPT-1 occurs in a PPAR-α independent manner. her paper) . A significant
component of butyrate’s biological activity is its ability to inhibit HDACs. The role
of butyrate as a HDAC inhibitor was evaluated on acetylation state of the CPT-1
and PGC-1 promoter. Particularly, the states of H3K9Ac were assessed since
this histone modification plays a key role in establishing transcriptionally
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permissive chromatin states. Specifically, H3K9Ac actively neutralizes the basic
charge of the affected lysine and ultimately leads to chromatin de-condensation,
making the DNA more accessible to transcription factors and RNA polymerases
leading to gene transcription. HDAC inhibitory property of butyrate increased the
H3K9 acetylation in the alcohol treated cells at TSS site on the CPT-1 and PGC1 promoter. The data obtained strongly supports that the changes in PGC-1 and
CPT-1 promoter H3K9Ac levels is achieved by the butyrate HDAC inhibitory
function. Additionally, the data support the notion that butyrate mediated increase
in H3K9Ac results into active transcription as seen by up regulation in CPT-1 and
PGC-1 mRNA levels.
The states of CPT-1 promoter H3K9Ac can be significantly enhanced by
PGC-1 co-activator function. PGC-1 is known to interact and recruit HATS such
as SC-1 and p300 [147, 148]. Besides PGC-1, p300 HAT can also be recruited
by the TF SP-1 which plays a role in maintaining the basal and inducible CPT-1
gene expression [150]. P300 is a well-known histone acetyl transferease (HAT)
and co-activator that plays a pivotal role in the transcription regulation of gene
expression [161, 162]. Indeed, commensurate with the butyrate mediated
increase in PGC-1 binding and H3K9Ac levels at the CPT-1 promoter, there was
an increase in the recruitment of p300. This reflected by the transcriptionally
permissive state of the CPT-1 promoter. This was shown by an increase in the
assembly of the pre-initiation complex represented by increased Sp-1 binding
and RNA-polymerase II. It is noteworthy that Sp-1 binds and recruits p300 HAT
and further influence the transcriptional state. According it is possible increase
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sp-1 binding would further contribute to a net increase in the histone acetylation
state of the promoter ultimately contributing to transcriptional activation of CPT-1
gene.
Overall, this data confirms the role of butyrate as an HDAC inhibitor by
increasing the net histone acetylation state of the CPT-1 promoter thereby
recruiting co-activators PGC-1 and p300 along with TFs and RNA-Pol II,
engaging the transcription machinery required for CPT-1 gene expression.
Further, after confirming the role of butyrate in alcohol-induced hepatic
steatosis we investigated the effect of tributyrin/butyrate on alcohol-induced
hepatic inflammation. TNF-α, a key cytokine involved in the development of
alcoholic liver disease was significantly down-regulated by tributyrin
administration as early as 2 weeks indicating that butyrate suppresses initial
inflammation caused due to alcohol consumption. Additionally, chemokines such
CCL-2/MCP-1 has been shown to be significant factors in various chronic
inflammatory diseases [163]. Recent studies have shown that MCP-1 regulation
shares a common link between inflammatory cytokines and lipid metabolism in
alcoholic liver disease [93]. In our animal model we have shown that CCL-2 was
induced by 2 weeks of alcohol-feeding and its high expression was maintained
up to 7 weeks. This indicates that CCL-2 regulation is involved in sustained
inflammation. Moreover, alcohol primed the hepatocytes and increases their
sensitivity to TNF-α inducible CCL-2 expression. Butyrate significantly downregulated CCL-2 induction indicating that butyrate can directly act on the
hepatocytes to suppress inflammatory chemokines. Potentially, butyrate being as
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HDAC inhibitor, could also be affecting acetylation of non-histone proteins
including certain transcription factors responsible for the induction of CCL-2.
NFκB is known to play a central role in immune and inflammatory responses and
is involved in transcriptional regulation of many chemokines and cytokines
including TNF-α. Suppression of LPS inducible TNF-α by butyrate in RAW cells
indicated that butyrate inhibits pro-inflammatory cytokine production in
macrophages. Hence we speculate that butyrate inhibits NFκB activation via
affecting its acetylation state and/or promoting IκBα degradation [133] leading to
resultant down-regulation of CCL-2 gene expression. In addition to NFκΒ, CCL-2
is also regulated by Activator protein-1. Hence butyrate could suppress CCL-2
expression by decreasing the DNA binding activity of NFκB and AP-1 onto the
CCL-2 promoter. Immunohistochemical analysis showed that butyrate
suppressed alcohol-induced neutrophil infiltration and macrophage activation as
shown by F4/80+ cells. Finally liver injury markers, AST and ALT were
significantly down-regulated by triburyrin administration indicating that tributyrin
prevented alcohol-induced early liver injury at 2 weeks as well as sustained injury
at 7 weeks.
Overall this data indicates that tribtyrin/butyrate through HDAC inhibition
significantly prevented alcohol-induced hepatic steatosis, inflammation and
injury.
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SUMMARY AND CONCLUSIONS
Work done in this thesis examines the role and the underlying molecular
mechanisms of Tributyrin in the attenuation of Alcoholic liver disease in mice.
Decades of research have shown that chronic alcohol abuse is associated with
alcoholic liver disease (ALD). Clinically, stages of alcoholic liver disease include
fatty liver, steatohepatitis followed by fibrosis and cirrhosis leading to
hepatocellular carcinoma. Hepatic steatosis is transient and temporary. If not
treated, it can progress into steatohepatitis leading to the development of
alcoholic liver disease. There is no FDA-approved therapy for any stage of
alcoholic liver disease. Hence it is of prime importance to understand the
mechanisms of Alcoholic liver disease which would lead us to a better
understanding of therapeutic intervention and further developing novel
strategies/therapies in the treatment of ALD. Hence in this project, we have
investigated the effects of Tributyrin supplementation; a pro-drug of butyrate in
attenuating alcohol induced hepatic steatosis, inflammation injury in mice.
Previous studies have shown that increase in the butyrate levels in the hepatoportal circulation prevents LPS-induced liver injury in rats. The hypothesis of this
project is that oral administration of tributryin targets the ‘gut-liver’ axis and
significantly blocks the progression of alcoholic liver disease (ALD).
We have used a well-established animal model of alcoholic liver disease
to examine the effects of Tb oral administration on ethanol-induced changes in
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intestinal permeability and hepatic steatosis, inflammation and injury. 8–10-week
old C57BL/6 male mice were pair-fed the Lieber-DeCarli liquid diet containing
alcohol or isocaloric maltose dextrin for a period of 7 weeks. Tributyrin was
administered to a sub-group of alcohol-fed animals by oral gavage to assess its
effects. In order to monitor the temporal changes in the progression of ALD,
these animals were sacrificed at 2, 4 and 7 weeks.
Initial analysis revealed Tributyrin attenuated the ethanol-induced gut
barrier dysfunction, as shown by the significant reduction in endotoxemia.
Mechanisms of chronic alcohol-induced gut-barrier dysfunction were examined
by the immune-histochemical analyses of the ileum section of mice chronically
fed alcohol. Specifically, alcohol induced a robust down-regulation of intestinal
tight junction proteins ZO-1 and occludin which was markedly attenuated by
Tributyrin. Additionally, Tributyrin treatment significantly decreased alcohol
induced hepatic steatosis as well as hepatic triglycerides. Tributyrin prevented
ethanol-induced down-regulation of CPT-1 gene expression (RT-PCR), a key
enzyme in fatty acid β-oxidation. Tributyrin being a prodrug is metabolized to
butyrate by pancreatic lipases. Butyrate is a HDAC inhibitor. To understand the
regulation of CPT-1 gene expression under pathogenic conditions experiments
were performed using primary rat hepatocytes. Hence acetylation at CPT-1
promoter was investigated. Acetylation of histone 3 lysine 9 (H3K9), a critical
feature of the active promoter state was suppressed by alcohol treatment in
hepatocytes reversed by butyrate. PGC-1 a critical co-activator of CPT-1 and Sp1, transcription factor binding to DNA was robustly increased by butyrate.
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Additionally, p300 a histone acetyl transferase was shown to be recruited at the
DR-1 binding site as well as TSS site on the CPT-1 promoter region indicating an
increase in the net acetylation. Hence butyrate being an HDAC inhibitor
increases the net acetylation state at the promoter region of CPT-1 gene leading
to its transcriptional activation and regulation.
Hepatic inflammation was markedly decreased in Tributyrin administered
alcoholic mice seen by liver immunohistochemistry staining. Myeloperoxidase
activity, a quantifiable measure of inflammation was significantly dampened by
Tributyrin. Tributyrin also attenuated the ethanol induced hepatic expression of
the critical inflammatory cytokine, TNF-α. Liver injury markers such as AST and
ALT were significantly attenuated at the end of 7 weeks in Tributyrin treated
mice. Moreover, Tributyrin also prevented the ethanol-induced expression of
chemo-attractant chemokines (CXCl2, CCl2 and ICAM-1), and neutrophil
recruitment that are critical for the development of ALD. Future studies are aimed
to understand the underlying mechanisms of how butyrate protects the gut and
the liver in alcohol fed animals.
Overall, the present work demonstrates that tributyrin may be useful in
preventing the ethanol-induced gut barrier dysfunction and associated pathologic
hepatic changes, and may prove to be a useful therapy for the
prevention/treatment for ALD.
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SECTION II
DETERMINE THE MECHANISMS OF HIV-ANTIRETROVIRAL
THERAPY INDUCED LIVER INJURY
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INTRODUCTION

HIV/AIDS- An overview
HIV (Human Immunodeficiency Virus) infection is considered pandemic by
the World Health Organization (WHO), claiming more than 25 million lives over
the past three decades. Thirty four million people are affected worldwide. Centre
for Disease Care (CDC) estimates 1.2 million people in the United States (US)
are living with HIV infection (www.cdc.gov). One in five (20%) of those people are
unaware of their infection. By race, African Americans face the most severe HIV
burden. Men having sex with men (MSM), particularly the young, are most
severely affected. HIV infection leads to AIDS (Acquired Immunodeficiency
Syndrome). AIDS was first recognized in the United States in the summer of
1981, when the U.S. (CDC) reported the unexplained occurrence of
Pneumocystis jiroveci (formerly P. carinii) pneumonia in five previously healthy
homosexual men in Los Angeles. In 1983, human immunodeficiency virus (HIV)
was isolated from a patient with lymphadenopathy, and by 1984 it was
demonstrated clearly to be the causative agent of AIDS. Since the epidemic
began, an estimated 1,108,611 people in the US have been diagnosed with AIDS
(www.cdc.gov).
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HIV and HAART
In order to prevent or delay resistance development in HIV infected
patients, physicians are using a regimen which consists of a combination of
several types of antiretroviral drugs that act on different sites on a retro virus and
also target different stages in the lifecycle of the virus. Such treatments are called
highly active antiretroviral therapy (HAART) [164]. The development of multi-drug
combination therapy for treatment of HIV disease is considered one of the great
success stories of modern medicine. In a period of approximately ten years, the
death rate from HIV disease was reduced by 50 to 80% [165]. HAART as
treatment for HIV infection has greatly improved mortality and morbidity for adults
and children living with HIV around the world [166, 167]. HAART is the only
treatment available to suppress the viral load. Currently used HAART medication
include nucleoside reverse transcriptaseitnhibitors (NRTIs) (zidovudine,
didanosine, abacavir), non-nucleoside reverse transcriptase inhibitors (NNRTI)
(nevirapine, etravirine), protease inhibitors (PI) (indinavir, ritonavir, lopinavir,
atazanavir), Fusion inhibitors (Enfuvirtide), Integrase Inhibitors (Raltegravir), and
CCR5 inhibitors all of which act on different sites on HIV facilitating a decrease in
viral load. Current treatment guidelines strongly recommends the use of tripledrug regimens which consists of two nucleoside reverse transcriptase inhibitors
(NRTIs) with either a protease inhibitor (PI) or a non-nucleoside reverse
transcriptase inhibitor (NNRTIs) as a first line option for the initial treatment of
early and advance disease progression [95]. Since the introduction of highly
active antiretroviral therapy (HAART) in the mid-1990s, the life expectancy of
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patients with HIV has increased significantly [168, 169]. Although HAART has
been widely used in the treatment of HIV, HIV infected patients have experienced
complications associated with HAART, which cannot be ignored. Antiretroviral
toxicity, resistance, and adherence rank high on the list of problems that must be
overcome if all, or at least the vast majorities, of HIV-infected patients are to gain
the long-term benefits associated with HAART [170]. Among these problems,
toxicity, real or perceived, is a major reason for patients either refusing or
prematurely discontinuing HAART [171]. The drop in mortality and morbidity due
to opportunistic infection has been accompanied by a concomitant increase in
HAART-related hepatotoxicity which caused discontinuation of HAART in
increasing numbers of patients. HAART hepatotoxicity, including lactic acidosis,
hepatic steatosis and lipodystrophy, occurs in approximately 10% of patients and
is higher in those with underlying liver disease [172].
Nucleoside Reverse Transcriptase Inhibotors (NRTI)- Nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs), inhibit the formation of viral DNA by
incorporating into the newly formed DNA molecules, thereby preventing further
elongation of those molecules [173].
Protease Inhibitor (PI) - Protease inhibitors block the activity of the protease
enzyme, which HIV uses to degrade large polyproteins into the smaller pieces
required for assembly of new viral particles. All PIs are metabolized in the liver by
CYP3A isoenzymes; consequently their metabolic rates may be altered in the
presence of CYP inducers or inhibitors. Co-administration of PIs with a potent
CYP3A inducer may lead to suboptimal drug concentrations and reduced

89

therapeutic effects of the PI. Hence co-administration of PIs with ritonavir (RTV),
a potent CYP3A inhibitor will optimally increase PI exposure. [174]. While HIV
can still replicate in the presence of protease inhibitors, the resulting virions are
immature and unable to infect new cells. PI –based regimen has seen
demonstrated to have anti-virologic potency. Unlike NRTI resistance, virologic
failure rarely selects for PI-resistance, which confers it with increased efficiency
in decreasing the viral load.
Ritonavir and Lopinavir- Protease inhibitors
Lopinavir is a novel PI developed from ritonavir. It is structurally related to
ritonavir with the same mechanism of action. Lopinavir has poor oral
bioavailability coupled with its extensive and rapid metabolism in the liver,
resulting in a short elimination half-life (t1/2). However, co-administration with
subtherapeutic doses of ritonavir improves these pharmacokinetic properties of
lopinavir allowing the drug to exert its highly potent antiretroviral activity [175,
176].
Mechanism of action of Protease inhibitors
Lopinavir is a higly potent inhibitor of HIV-1 protease [177, 178]. This
enzyme is a homodimeric aspartic protease involved in the post-translational
processing of viral gag and gag-pol polyprotein products into functional core
proteins and viral enzymes [179]. HIV PIs, including lopinavir, prevent cleavage
of gag and gag-pol protein precursors in acutely and chronically infected cells,
arresting maturation and thereby blocking the infectivity of nascent virions [180,
181].
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HAART associated hepatotoxicity and liver injury
HAART causes a variety of adverse effects like cardiovascular diseases,
neurological disorders, liver disease, lipodystrophy, non-Hodgkin lymphoma to
name a few. Liver disease is recognized as an increasingly important problem for
the HIV population, and may be due to a variety of factors including co-infection
with viral hepatitis, alcohol abuse, and antiretroviral hepatotoxicity. Liver disease
is now a leading cause of death for patients with HIV. In patients co-infected with
HIV and hepatitis C, cirrhosis was the underlying cause of death in nearly 50%
[171]. In a more general HIV population, liver disease was the second most
common non-HIV-related cause of death, trailing only cancer [182]. The earlier
retrospective study showed that the discontinuation of ART due to hepatotoxicity
increased from 6% in 1996 to 31.8% in 1998-1999 and was the main cause of
death in HIV infected individuals [183]. The severity of liver toxicity ranges from
the absence of symptoms to liver decompensation, and the reported incidence of
severe liver toxicity after initiating HAART ranges from 2% to 18%. Hepatotoxicity
due to HAART is also common and up to 30% of patients on HAART experience
World Health Organization grade 3 liver enzyme elevations. Hepatotoxicity
induced by these agents has been identified on the basis of circulating liver
enzymes (ALT, AST, and GGT) in association with increased lactate levels. In
more dramatic situations, liver failure has occurred leading to discontinuation of
treatment. The study of hepatotoxicity induced by HAART is complicated by the
diverse chemical nature of the agents and by the differences between the effects
of agents used singly or in combination. Hepatotoxicity from antiretroviral drugs
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has led to adverse patient outcomes either from fulminant hepatic failure, or more
commonly, AIDS following discontinuation of HAART. Mechanisms contributing
to the adverse effects of HAART induced hepatotoxicity are still largely
undetermined. Hence, it is highly relevant to study the underlying mechanisms of
HAART-induced hepatotoxicity.
Role of ER-stress in HIV-PI induced liver injury
Recent evidence suggests that HIV-PIs induce ER-stress and promote
liver injury [184-186]. The ER is a critical organelle responsible for proper protein
folding, cellular calcium levels, lipid synthesis and the secretory pathway. ER
stress is primarily mediated by the ER protein BiP/GRP78 (Glucose regulated
protein 78) via three ER sensors ATF6 (activating transcription factor 6), IRE-1
(inositol-requiring enzyme1), and PERK (protein kinase RNA-like endoplasmic
reticulum kinase). ER stress comprises both pathologic and adaptive responses;
UPR adaptive responses reduce the protein burden by decreased synthesis and
increased ER-associated degradation (ERAD) of proteins, and by inducing ER
chaperones to enhance folding capacity. If the adaptive/protective reactions are
inadequate or if the ER stress is prolonged/extreme, apoptotic cell death ensues
via pathways involving activation of JNK (cJun N-terminal kinase) and caspase12, and upregulation of proapoptotic proteins like CHOP (CCAAT/enhancerbinding protein homologous protein)[187]. CHOP also known as growth-arrest
DNA damage-inducible gene 153 (GADD153) is a major transcription factor
involved in ER-tress mediated apoptosis [188].
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HIV PIs, individually or in combination were shown to increase ER-stress
markers such as active sterol regulatory element-binding proteins (SREBPs), X
box binding protein 1 (Xbp1), activating transcription factor 4 (ATF-4), C/EBP
homologous protein (CHOP) and caspase-12, leading to apoptosis in
macrophages and rat hepatocyte. Additionally, ER calcium store depletion and
lipid dysregulation in the ER by HIV PIs were shown to activate unfolded protein
response in the hepatocytes [184, 185, 189]. Co-factors such as alcohol or
Hepatitis C or B virus may exacerbate HIV-PIs induced ER-stress and liver injury.
Role of Fas/FasL pathway in drug induced liver injury
Liver is an important organ for metabolism and elimination of foreign
substances. Hence it is targeted for drug toxicity. Excessive hepatocyte cell
death has been shown to be the central mechanism of liver damage in conditions
such as viral hepatitis; alcoholic steatohepatitis, non-alcoholic steatohepatitis
(ASH and NASH) as well as drug induced liver injury (DILI). The Fas/FasL
signaling pathway has been implicated in various liver pathologies including
Wilson’s disease, alcoholic liver disease (ALD), acute fulminant hepatitis, as well
as chronic viral hepatitis [190-192]. Fas (CD95) is a death receptor in the tumor
necrosis factor receptor (TNFR) family and is expressed in a variety of
tissue[193]. Upon binding, the receptor undergoes trimerization and forms the
intracellular death-inducing signaling complex (DISC) [193, 194]. This DISC
include Fas-associated protein with death domain (FADD). This activates
caspases signaling cascade via mitochondria dependent and independent
pathways leading to apoptotic cell death [193]. Typically hepatocytes express
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high levels of Fas receptor and respond to FasL signals from activated immune
cells; however, under pathologic conditions such as alcoholic cirrhosis,
hepatocytes also express high levels of FasL, leading to fratricide and liver injury.
Moreover, endotoxin-induced liver injury in mice occurs via the Fas/FasL
pathway following induction of Fas by IL-18 from Kupffer cells, and hepatocyte
death induced in mice following exposure to anti-Fas antibody (JO-2) is an
accepted model of fulminant hepatitis. With regards to HIV-positive individuals,
increased expression of FasL is seen in cardiomyocytes, which contributes to
AZT-Induced cardiomyopathy [195].
Role of Phosphodiesterase 4 (PDE4)/cAMP in liver injury
cAMP is a second messenger that plays a critical role in regulating
multiple cellular functions and its levels are tightly regulated through biosynthesis
by adenyl cylases (ACs) and hydrolysis by phosphodiesterase (PDEs). cAMP
exerts its effect through effector molecules protein kinase A (PKA) and
Exchange Protein directly Activated by cAMP (EPAC), also known as cAMPGEF. There are 11 different members of the mammalian class I PDE super
family, (PDE1-PDE11); within the families there are multiple genes and a large
number of PDE splicing variants. Distinct kinetic and functional properties are
attributed to PDE families with some specifically hydrolyzing cAMP, some both
cAMP and cGMP, and others only cGMP [196, 197]. Of the cAMP specific PDEs,
the PDE4 family is widely expressed and is the current therapeutic target for the
treatment of inflammatory diseases, such as asthma and chronic obstructive
pulmonary disease, as well as depression and cognitive deficit [197, 198].
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PDE4 accounts for the majority of cAMP hydrolysis activity in cells[199]. PDE4
represents a large and complex family, with 4 genes (PDE4A/B/C/D) encoding
over 20 distinct PDE4 isoforms as a consequence of distinct promoter usage and
mRNA splicing; notably, these isoforms have similar catalytic activities but
distinct cellular functions. PDE4 isoforms are regulated by transcriptional and
post-translational mechanisms. Work done in our lab has shown that PDE4
expression is significantly increased in response to alcohol exposure in
monocytes/macrophages including hepatic Kupffer cells [200]. Notably, Work
done by us and others has shown that regulation of cellular cAMP levels via
degradation by phosphodiesterase (PDEs), particularly cAMP-specific
PDE4B plays an essential role in LPS-induced TLR4 signaling and
inflammatory cytokine expression by monocytes/ macrophages [201-203](Jin and
Conti, 2002; Jin et al., 2005; Gobejishvili et al., 2011). Additionally, in cholestatic
liver injury, besides downregulating systemic and hepatic inflammatory cytokines,
increases in cAMP have been shown to protect hepatocytes from apoptosis due
to several related stimuli, including bile acids, LPS, Fas, and TNF-α [204-207].
In another study done by our lab bile duct ligation mediated liver injury and
apoptosis was significantly attenuated by PDE4 inhibition as assessed by
reduced liver enzyme levels, decreased TUNEL staining, and PARP-1 cleavage.
Hence, in addition to its anti-inflammatory effects, PDE4 inhibition, which leads to
increased cellular cAMP levels, could also attenuate hepatocyte death. Indeed,
cAMP has been shown to protect hepatocytes from bile acid–induced death by
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affecting protein kinase A (PKA) and cAMP-guanine exchange factor–mediated
signaling [206-208].
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OVERALL HYPOTHESIS
We hypothesized that Protease inhibitor induced PDE4 expression and altered
cAMP metabolism plays a major role in the induction of hepatocyte ER-stress,
apoptotic gene expression and injury. (Fig. 30)

Fig. 30
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SIGNIFICANCE & CLINICAL RELEVANCE
In the United States, approximately 2000 cases of acute liver failure occur
annually and drugs account for over 50% of them (39% are due to
acetaminophen, 13% are idiosyncratic reactions due to other medications).
Drugs account for 2-5% of cases of patients hospitalized with jaundice and
approximately 10% of all cases of acute hepatitis. HAART has been associated
with increase in morbidity and mortality due to HAART-related hepatotoxicity and
finally discontinuation of therapy. This is especially true in patients who are coinfected or have other cofactors such as alcohol abuse. The mechanisms for
HAART hepatotoxicity have received very limited attention. There is no wellaccepted therapeutic intervention except for abstinence and HAART
discontinuation. Since liver is the first organ exposed and metabolized by the
drugs it becomes highly relevant to understand the mechanism of drug toxicity.
Findings from this project could provide important mechanisms by which HAARTPI induced pathology causes cell death in hepatocyte often observed by
prolonged drug intake in HAART medication. Moreover, the findings from this
study would be significant in the development of successful preventive and
therapeutic strategies in most-at-risk populations. Finally, the proposed studies
will focus on direct hepatotoxicity due to HAART by the combinations of ritonavir
and lopinavir (HAART PIs drugs), defining the disease mechanisms and
generate therapeutic targets.
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MATERIALS AND METHODS
Reagents
PI drugs Ritonavir and Lopinavir were purchased from Selleckchem (Houston
TX). Rolipram was purchased from Enzo Life sciences (Farmingdale, NY). H-89
and Dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis,
MO). Horse serum was purchased from ATCC. Fetal bovine serum was
purchased from Atlanta Biologicals (Norcross, GA). DMEM, penicillin,
streptomycin and TRlzol® were obtained from Invitrogen (Carlsbad, CA). All RTPCR reagents were purchased from Applied Biosystems (Foster City, CA). MTT
(Thiazolyl Blue Tetrazolium Bromide) was obtained from Sigma-Aldrich (St.
Louis, MO).
Cell Culture
H4IIEC3 rat hepatoma cells (ATCC, Rockville, MO) were cultured in Dulbecco's
modified eagle medium (DMEM) supplemented with 10% Horse Serum and 5%
fetal bovine serum (FBS), 10 U/ml penicillin, and 10~g/ml streptomycin. Cells
were maintained in an incubator at 37°C with humidified 5% CO2. Cells were
plated and incubated overnight before treatment, in all experiments.
Cell Survival Assay
The MTT assay was used to assess cell survival. For the MTT assay, cells were
plated in 96 well microplates, incubated overnight and treated with the treatments
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mentioned in results for 24 hours. Treatments were then removed and MTT
made in fresh DMEM (1 mg/ml) was added to the wells (100 µl/well). After
incubation at 37°C with humidified 5% CO2 for 1-3 hours, DMSO (200 µl/well)
was added. Cell viability was quantified colorimetrically by measuring 0.D. at 570
nm.
RNA Isolation and Real-Time PCR Analysis
Total RNAs were isolated from liver tissue and cell cultures using TRIzol reagent
(Invitrogen, Carlsbad, CA) and treated with DNase I to remove any contaminating
genomic DNA (RQ1 RNase-Free DNase; Promega). For RT-qPCR, the firststrand cDNA was synthesized using qScript cDNA SuperMix (Quanta
Biosciences, Inc., Gaithersburg, MD). qRT-PCR was performed in triplicate with
an ABI Prism 7500 sequence detection system and Perfecta SYBR Green
FastMix, Low ROX reagents (Quanta Biosciences). The RT conditions were 10
mins at 25°C, 30mins at 48°C and 5 mins at 85°C. Each sample was run in
duplicate reactions. Reverse transcriptase polymerase chain reaction (RT-PCR)
assays were used to assess mRNA levels of desired genes in liver tissues as
well as hepatocytes H4IIEC3 cells. The primers amplifying the genes examined
were designed in the lab and obtained from Intergrated DNA Technologies, Inc
(Coralville, IA). The parameter threshold cycle (Ct) was defined as the fraction
cycle number at which the fluorescence passed the threshold. The relative gene
expression was analyzed using the 2-AACt method by normalizing with β-actin
mRNA gene expression in all the experiments and is presented as fold change
over Untreated which is set at 1.
100

Western Blot analysis
Total cellular extracts were prepared by lysing the cells in RIPA lysis buffer
(25mM Tris/HCL pH 7.5, 150mM NaCl, 1% NP-40, 0.1% SDS, 1mM DTT, 10%
glycerol, 1x protease inhibitor cocktail, 0.5% sodium deoxycholate, 1mM Na2VO3
and 10mM NaF). Protein samples were prepared in SDS loading buffer and
proteins were separated by electrophoresis on 10% polyacrylamide gels and
transferred onto a PVDF membrane. The blots were blocked with 5% (w/v)
nonfat dry milk constituted in 1x TBS-T (Tris buffered saline, 10mM Tris HCL pH
8.0, 150 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. Membranes
were incubated at 4°C overnight with primary antibodies directed against proteinof-interest in 5% (w/v) nonfat dry milk in 1x TBS-T. After overnight incubation in
primary antibod, blots were washed and incubated with appropriate horseradish
peroxidase-conjugated secondary antibodies for an hour. Immunoreactive bands
were visualized using the enhanced chemiluminescence light (ECL) detection
reagents (Amersham, Arlington Heights, IL). Data shown are representative of 2
separate experiments showing similar results. Primary antibodies for AFT3, 4
CHOP, PDE4A, B D and FasL were purchased from cell signaling. β-actin
antibody was obtained from Sigma-Aldrich (St. Louis, MO). Secondary antibodies
against mouse and rabbit were obtained from Santacruz Biotechnologies, Inc.
(Santacruz, CA).
Statistical Analysis
Data are presented as means± SD for the indicated number of independently
performed experiments. Student's t-test and one-way ANOVA with Bonferroni
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multiple comparison test were used for the determination of statistical
significance. P<0.05 was considered significant.

mRNA PCR Primer Sequences
primer name
rATF3_F1
rATF3_R1

Sequence
GGGCCACCTCAGACTTGGTGACT
CATCGGATGTCCTCTGCGCTGG

rATF4_F1
rATF4_R1

AAGCCATGGCGCTCTTCACGA
AGTCCCCCGCCAACACTTCG

rDDIT3_GADD_CHOP_F1 TGTTGAAGATGAGCGGGTGGCAG
rDDIT3_GADD_CHOP_R1 TGGACCGGTTTCTCTCTCCTCAGGT
r.n_FasL_F1
r.n_FasL_R1

CTCTGGTTGGAATGGGGTTA
TTGGTTTCAGAGGGTGTGCT

r.n._Fas_F2
r.n._Fas_R2

CATTTTGCTGTCAACCGTGT
CGTGTACTCCTCCCCTTCTG

rActb_F2
rActb_R2

CAGCTGAGAGGGAAATCGTG
CTCCAGGGAGGAAGAGGATG

rPde4acm1_F
rPde4acm1_R

ATGGCTGAGTTCTTCCAGCA
CCATGTCTCCCACAATGGAT

rPde4bcm2_F
rPde4bcm2_R

GGAGTTGTATCGGCAATGGA
CAATGAAACCAACCTGGGACT

rPde4dcm1_F
rPde4dcm1_R

TGGATCATCCTGGTGTGTCA
TTAAAGCCCACAGCCAAATG
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RESULTS
In this study we investigated the mechanisms involved in HIV-PI induced
hepatotoxicity. We specifically examined the role of ER-stress and apoptotic
Fas/Fas expression in the HIV-PI mediated hepatocyte death. Importantly, we
determined the pathogenic role of PDE4 /cAMP metabolism in the development
of HIV-PI-induced hepatotoxicity.
HIV-protease inhibitors induces PDE4 expression in H4IIE rat hepatoma cell
line
Work done by our research group has demonstrated that PDE4 expression
leading to a decline in cellular cAMP levels plays a major pathogenic role in the
development of alcohol induced liver disease and cholestasis liver injury and
fibrosis [200, 209]. Hence we investigated the involvement of PDE4 enzymes in
PI-induced hepatotoxicity. mRNA gene expression was carried out to profile the
expression of PDE4 sub-families A,B and D in H4IIE hepatocytes treated with
Ritanovir (Rit) and Lopinavir (Lop) (20µM) each singly and in combination.
Differential pattern of the gene expression in PDE4 sub-family member was
observed (Fig.31). Specifically, PDE4B gene expression was induced as early as
3hrs by the combination treatment of Rit and Lop. PDE4B expression was
observed to go back to baseline by 6 hours. In contrast PDE4A and PDE4D
mRNA expression was only observed to be significantly induced by the PI
combination at 24hrs in the combinatorial treatment of Ritanovir and Lopinavir
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(20µM). Further, in correspondent to the changes in mRNA expression the
combination of PI drugs showed an increase in PDE4B and PDE4D protein
expression as shown by western blot analysis (Fig31); interestingly PDE4A
protein expression did not show an appreciable change in the cells treated with
PIs together at 24hours. Since western blot data was done only at 24hrs,
possibility of PDE4A induction by PI drugs at early time-points or time-points after
24hrs cannot be ruled out. Overall this data suggests that PIs in combination
induce PDE4 expression in hepatocytes that can affect cAMP metabolism.
Inhibition of PDE4 led to a significant increase in the survival of HIV-PI
treated H4IIE rat hepatocytes
Cell viability was measured in hepatocytes treated with individual drugs
(Ritanovir 20uM or Lopinavir 20uM) and combination (Ritanovir and Lopinavir
20uM each) for 24hrs. The effect of PDE4 inhibition was examined by adding
rolipram along with Rit+Lop combined treatment. Individual drugs Ritanovir and
Lopinavir decreased cell viability by 30% whereas combination of drugs
(R+L20uM) further significantly decreased it by 55% as compared to untreated
(Fig.32). However addition of rolipram along with (Rit+Lop) prevented the loss of
hepatocyte and increased survival upto 65% (Fig.32). This data indicates that
(Rit and Lop) singly and in combination induces cell death in hepatocytes
whereas inhibition of PDE4 by the addition of rolipram significantly increased the
cell survival in H4IIE cell line.
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Fig. (31) HIV-PI drugs induce PDE4A, B and D mRNA and protein expression:
H4IIE cells were exposed to Ritonavir (Rit)20µΜ and Lopinavir (Lop)20µΜ singly
and in combination with or without Rolipram (Rol)10µM at the above mentioned
time points. mRNA expression was examined by real-time PCR using primers
specific for PDE4A, B and D. Data represented as the mean ± SE (n=5).
Statistical analysis was performed using GraphPad Prism software using oneway ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ when compared to
untreated (UT) ‘d’ when compared to Rit+Lop. Western blot analysis of PDE4A, B
and D was performed using total cell lysates. GAPDH was probed to ensure
equivalent protein loading. Densitometry analysis was performed using
ImageLab software. Density ratio was calculated using β-actin as control. Blots
are representative of two independent experiments.
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Fig.(32) HIV-PI induced hepatocyte death is partially reversed by Rolipram: H4IIE
cells were exposed to Ritonavir (Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in
combination with or without Rolipram (Rol)10µM in a 96 well format for 24hrs.
Loss of hepatocyte survival was measured by MTT assay and plotted as a bar
graph with 100% survival rate in UT cells. Data represented as the mean ± SE
(n=4). Statistical analysis was performed using GraphPad Prism software using
one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ when compared to
untreated (UT) ‘d’ when compared to Rit+Lop.
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HIV-PIs induced ER-Stress was significantly attenuated by PDE4 inhibition
Previous studies have shown that HIV-PI induces ER-stress and unfolded protein
response (UPR) and apoptosis in hepatocytes [185, 210]. Specifically, the
combination of HIV-PI ritonavir and lopinavir significantly activated UPR in
various hepatic cells; hence, we investigated the role of phosphodiesterase in
HIV-PI induced ER-stress. Studies have also shown that CHOP knockout mice
were protected from HIV-PI induced ER-stress, inflammation and hepatic
lipotoxicity [211]. Prolonged translation of ATF4 and 3 was shown to be
responsible for CHOP transcription [212]. We investigated the effect on ATF3, 4
and CHOP as hallmark ER-stress proteins in HIV-PI treated cultured
hepatocytes. H4IIEC3 cells were treated with Rit and Lop (20µM each) singly and
in combination for a period of 6, 12 24 and 48hrs. Our results showed a
sustained induction of ER-stress genes ATF3, ATF4 and CHOP from 6hrs to
48hrs of PI drug exposure. Although, we did not report any significant increase of
ER-stress genes by individual drugs, a trend was seen. Additionally this data was
further confirmed by western blot analysis (Fig.33a,b,c,d). To address the causal
role of PDE4 expression in the induction of ER-stress by PI drugs, PDE4
specific/selective inhibitor Rolipram was used. Rolipram (10uM) treatment was
shown to significantly down-regulate the induction of PI-induced ER-stress
markers at gene as well as protein level for all the time-points. This data
indicated that PDE4 expression induced by PI drugs is playing regulatory role in
the induction of ER-stress.
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PIs induces Fas Receptor and FasL gene expression in hepatocytes
Fas/Fas Ligand signaling is one of the most critical pathways involved in
apoptosis induced cell death in hepatocytes[213]. Moreover, previous reports
have shown the mechanistic link between proapoptotic ER-stress and the Fas
and mitochondrial pathways of apoptosis via CamKII signaling [214]. CamKII
signaling activates Fas receptor mediated apoptosis process in ER-stressed
macrophages thus providing an unifying mechanistic link between UPR and
apoptosis. Hence along with ER-stress expression we also investigated the role
of Fas/FasL pathway in the PI-mediated apoptotic cell death in the hepatocytes.
We did not report any significant up-regulation of FasL in Ritanovir and Lopinavir
at 20µM treated individually. However, cells treated with the combination of
Ritanovir and Lopinavir at 20µM significantly induced FasL gene expression at
24hrs that was further up regulated at 48hrs. We did not get any significant
induction of FasL gene expression at 6 and 12hrs suggesting that pro-apoptotic
FasL signaling was occurring only at later time-points (data not shown).
Moreover, Western blot analysis revealed that FasL protein expression was
markedly increased in the combinatorial treatment of PI as compared to
untreated in the hepatocytes. Similarly, Fas R was also significantly up-regulated
by PI combinatorial treatment on the hepatocytes. Rolipram treatment
significantly reversed this PI-drug induced up-regulation. This data showed for
the first time that cAMP depletion/PDE4 inhibition could have an influence on
Fas/FasL mediated drug-induced cell death in the hepatocytes (Fig 34).
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PDE4 inhibition down-regulates FasL expression in the hepatocytes
Previously, we have shown that PIs modulate PDE4/cAMP levels in the
hepatocytes. Hence we wanted to investigate the role of PDE4/cAMP
metabolism in regulating FasL gene expression. Rat hepatocytes were treated
with Rit/Lop and rolipram. As expected, FasL gene expression as well as protein
was completely abrogated by Rolipram (Fig.34). This data indicates that FasL
plays a major role in PI induced cell death in hepatocytes and more importantly,
PDE4 inhibition via rolipram significantly protected hepatocytes by downregulating FasL-induced cell death.
Role of cAMP-PKA signaling in PI induced ER-stress and FasL mediated
cell death in hepatocytes
Previously, we have shown that ER-Stress as well as FasL-mediated cell death
is regulated by PDE4 expression. In an assumption that the PI drugs
compromised cellular cAMP levels we investigated the role of cAMP signaling in
PI-induced upregulation of ER-stress and FasL expression. cAMP exerts its
downstream effects by phosphorylating and activating its targets such as protein
kinase A (PKA) and Exchange proteins activated by cAMP (EPAC). Hence to
determine whether cAMP-PKA signaling is involved in PI-induced ER-stress in
hepatocyte we examined the effects of a PKA inhibitor (H-89) (5uM) along with
HIV-PI and rolipram. H4IIEC3 cells were treated with Rit +Lop with/without
rolipram. As shown previously, rolipram treatment significantly down-regulated
ER-stress genes ATF3, 4 and CHOP as well as FasL at 24hrs. Addition of H-89
to rolipram and PI-treated cells significantly reversed the rolipram effect of ERstress and FasL suppression (Fig. 35). This data suggests that cAMP-PKA could
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play a key role in regulating ER-stress and FasL mediated cell death in
hepatocytes. We also speculate that PI drugs could be affecting PKA
phosphorylation leading to its inactivation in the hepatocytes and thus affecting
cAMP/PKA signaling.
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Fig. (33a) HIV-PI mediated ER-stress gene, ATF4 expression is down-regulated
by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir (Rit)
20µΜ and Lopinavir (Lop) 20µΜ singly and in combination with or without
Rolipram (Rol) 10µM at the above mentioned time points. mRNA expression was
examined by real-time PCR using primers specific for ATF4. Data represented as
the mean ± SE (n=5). Statistical analysis was performed using GraphPad Prism
software using one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’
when compared to untreated (UT) ‘d’ when compared to Rit+Lop.
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Fig. (33b) HIV-PI mediated ER-stress gene ATF3 expression is down-regulated
by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without
Rolipram (Rol)10µM at the above mentioned time points. mRNA expression was
examined by real-time PCR using primers specific for ATF3. Data represented as
the mean ± SE (n=5). Statistical analysis was performed using GraphPad Prism
software using one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’
when compared to untreated (UT) ‘d’ when compared to Rit+Lop.
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Fig. (33c) HIV-PI mediated ER-stress gene CHOP expression is down-regulated
by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without
Rolipram (Rol)10µM at the above mentioned time points. mRNA expression was
examined by real-time PCR using primers specific for CHOP. Data represented
as the mean ± SE (n=5). Statistical analysis was performed using GraphPad
Prism software using one-way ANOVA followed by Bonferroni posttest. P<0.01.
‘a’ when compared to untreated (UT) ‘d’ when compared to Rit+Lop.
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Fig. (33d) HIV-PI mediated ER-stress protein expression is significantly
attenuated by PDE4 inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without
Rolipram (Rol)10µM at 24hrs. Western blot analysis of ATF3, ATF4 and CHOP
was performed using total cell lysates. GAPDH was probed to ensure equivalent
protein loading. Densitometry analysis was performed using ImageLab software.
Density ratio was calculated using GAPDH as control. Blots are representative of
two independent experiments.
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Fig (34) HIV-PI mediated Fas and FasL expression is down-regulated by PDE4
inhibitor, Rolipram: H4IIE cells were exposed to Ritonavir (Rit)20µΜ and
Lopinavir (Lop)20µΜ singly and in combination with or without Rolipram
(Rol)10µM at the above mentioned time points. mRNA expression was examined
by real-time PCR using primers specific for FasL and Fas. Data represented as
the mean ± SE (n=5). Statistical analysis was performed using GraphPad Prism
software using one-way ANOVA followed by Bonferroni posttest. P<0.01. ‘a’
when compared to untreated (UT) ‘d’ when compared to Rit+Lop. Western blot
analysis of FasL was performed using total cell lysates. β -actin was probed to
ensure equivalent protein loading. Densitometry analysis was performed using
ImageLab software. Density ratio was calculated using GAPDH as control. Blots
are representative of two independent experiments.
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Fig (35) PKA inhibitor H-89 significantly reversed the protective effect of Rolipram
on ER-stress and FasL gene expression: H4IIE cells were exposed to Ritonavir
(Rit)20µΜ and Lopinavir (Lop)20µΜ singly and in combination with or without
Rolipram (Rol)10µM along with PKA inhibitor H-89 (5µΜ) at 24hrs. mRNA
expression was examined by real-time PCR using primers specific for ER stress
gene ATF4,3, CHOP and FasL. Data represented as the mean ± SE (n=5).
Statistical analysis was performed using GraphPad Prism software using oneway ANOVA followed by Bonferroni posttest. P<0.01. ‘a’ when compared to
untreated (UT) ‘b’ when compared to Rit+Lop and ‘c’ when compared to
Rit+Lop+Rol.
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DISCUSSION
HIV-protease inhibitors are used as combinatorial therapy and have
significant therapeutic potential in the treatment of HIV-infection [215]. However,
the prolong use of PIs has significant hepatotoxic effects [183]. Although, PIinduced hepatotoxicity has been examined, the underlying mechanisms are not
yet fully elucidated. Previous studies have shown that PI-induced endoplasmic
reticulum (ER) stress response play an important role in the development of
inflammation, dyslipidemia, and insulin resistance [185, 216-219]. In the present
work, molecular mechanisms driving PI-induced ER stress were investigated.
Specifically, since combination of Rit and Lop constitutes a common PI-treatment
regimen for HIV patients, their hepatotoxic effects were examined. The dose of
Rit (20 μM) and Lop (20 μM) employed in the present studies was based on
earlier clinical and experimental findings of anti-viral efficacy and hepatotoxicity
[184, 185, 220-222]. As seen in earlier studies, our initial examination of the
effect of Rit and Lop on hepatocytes showed that their combination was able to
significantly induce ER stress. Particularly, expression of critical ER-Stress
proteins such as ATF3, 4 and a known pro-apoptotic protein GADD153/CHOP
were significantly up-regulated. To address the mechanisms underlying PIinducible ER stress we investigated the potential role of PDE4 expression that
leads to a decline in cellular cAMP levels. The rationale for examining PDE4
expression was provided by the earlier studies done by our research group [203].
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These studies have demonstrated the major pathogenic role of PDE4 expression
and cAMP metabolism in experimental alcoholic liver disease and cholestatic
liver inflammation, injury and fibrosis [203, 209, 223]. Additionally, work done by
others has shown that increased cellular cAMP levels can effectively block
hepatocyte apoptotic death induced by various stimuli including bile-acids, Fas
and TNF [209, 223, 224]. Our data showed that Phosphodiesterase 4 (PDE4)
plays a pathogenic role in PI-induced ER stress and apoptotic cell death in
hepatocytes. Treatment of hepatocytes with the combination of Rit and Lop
(Rit+Lop) differentially induced the expression of PDE4 subfamily members.
Specifically, PDE4B mRNA expression was observed to be induced as early as
3hrs post-treatment, whereas, there was a significantly delayed induction of
PDE4A and D mRNA expression occurring at 24 h. Interestingly, examination of
protein expression revealed only PDE4B and D subfamily members at 24 h.
Since PDE4 members are the major cAMP-specific phosphodiesterase, their
rapid and sustained induction by PIs potentially represents a pathogenic event
decreasing hepatocyte cAMP levels and downstream signaling. Since we
observed an increase in the expression of both PDE4s and ER stress proteins in
Rit+Lop treated hepatocytes, it is possible that PDE4 upregulation and ER-Stress
are causally linked. The causal role of PDE4 was investigated by pre-treating the
hepatocytes with Rolipram – a PDE4 specific inhibitor. Notably, PDE4 inhibition
was able to abrogate Rit+Lop induced expression of ER stress genes and
significantly enhanced hepatocyte survival. These data identify for the first time,
PDE4 expression as the key mechanism that underlies PI-inducible ER stress
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and hepatotoxicity. With regards to ER stress mediated cell death, the induction
of pro-apoptotic GADD153/CHOP is well correlated with the onset of ER stressassociated apoptosis and has been observed to be induced by Rit+Lop in
hepatocytes [225-227]. However, besides induction of GADD153/CHOP, ER
stress has also been linked to Fas and mitochondrial apoptosis pathways [214].
Importantly, Fas-FasL mediated hepatocyte death has been demonstrated to
contribute to drug induced hepatocyte cytotoxicity [228, 229]. Also, in relevance
to this study, it has been demonstrated that cAMP inhibits FasL expression and
apoptotic cell death in lymphocytes [230]. Since we identified that Rit+Lop
significantly induces cAMP degrading PDE4 expression that is causally linked
with the development of ER stress, we further examined the effect on Fas and
FasL expression. The data obtained showed for the first time that Rit+Lop can
significantly induce the expression of both Fas and FasL that are known to
induce apoptosis and hepatocyte death. Notably, PDE4 expression was also
determined to play a causal role in the Rit+Lop-inducible Fas and FasL
expression. Inhibition of PDE4 leads to increased cellular levels of cAMP and a
major component of the cellular effects of cAMP are mediated by cAMP
dependent PKA (cAMP-PKA) activation and signaling [231]. Accordingly, our
data suggested that the inhibitory effect of PDE4 inhibition decreasing ER stress,
Fas and FasL expression could be mediated via cAMP-PKA activation. This
aspect was evaluated by examining the effect of cAMP-PKA inhibitor on
hepatocytes that were treated with Rit+Lop and Rolipram. The data obtained
strongly suggests that cAMP-PKA activity is essential for the prevention of ER
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stress, Fas and FasL expression and hepatotoxicity induced by combinatorial PI
(Rit+Lop) treatment. Taken together, these data demonstrate that PDE4
expression and consequent decrease in cAMP-PKA activation/signaling, plays a
key pathogenic role in the induction of Rit+Lop hepatotoxicity by both individually
or coordinately activating ER stress and Fas/FasL expression. Significantly,
these data also suggest that targeting PDE4 activity has therapeutic potential in
the treatment of PI-induced hepatotoxicity in HIV-infected patients.
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SUMMARY AND CONCLUSIONS
In the present study we investigated the role of Phosphodiesterase 4
(PDE4) and ER-Stress as significant pathogenic mechanism in Highly Active
Anti-retroviral Therapy (HAART) Induced Hepatotoxicity. The main purpose of
HAART is to significantly improve the quality of life by suppressing the viral load
and its replication in the body of an HIV (Human Immunodeficiency Virus)
infected individual. This is achieved by administering multiple drug therapy used
in HAART. Protease Inhibitors (PIs) are being used as one of the therapies in
the initial treatment of HIV infection. Even though these drugs have a positive
impact on the patients, they are associated with several undesirable
consequences in their long-term treatment. Some of the major complications of
HAART are hepatotoxicity and lipodystrophy leading to its discontinuation.
Hence it becomes highly relevant to investigate the mechanisms involved in PI
induced hepatotoxicity. Recent studies have shown the involvement of ER stress
and subsequent activation of the unfolded protein response (UPR) resulting in
apoptosis/hepatocyte death as one of the cellular mechanisms of HIV-PI induced
metabolic disorders.
Additionally, cAMP is a known anti-apoptotic or a pro-survival signal in
many different cell types including hepatocytes. Specifically in hepatocytes,
cAMP is involved in the protective mechanism from various insults such as Fas
Ligand, TNF-α, and hydrophobic bile acids. Our recent work shows that
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PDE4/cAMP metabolism plays a significant role in alcohol-induced hepatic
steatosis and injury. Phosphodiesterase (PDEs), a family of enzymes precisely
regulates intracellular levels of cAMP via adenylyl cyclase are involved in their
synthesis as well as degradation. Our recent work shows that PDE4/cAMP
metabolism plays a significant role in alcohol-induced hepatic steatosis and
injury. Hence in the present study, we examined the mechanisms underlying
HIV-PI induced hepatic ER stress and toxicity with a particular emphasis on
PDE4 family of enzymes.
The effects of clinically used HIV-PIs (Ritonavir and Lopinavir) were
examined both in a rat hepatoma cell line as well as rat primary hepatocytes.
These studies demonstrated that PIs led to a significant loss of hepatocyte
survival. Notably, inhibition of PDE4 by a specific PDE4-inhibitor, rolipram,
markedly attenuated hepatotoxicity induced by PIs. Mechanistic role of PDE4
showed that PDE4 inhibition significantly decreases the expression of the ER
stress related proteins C/EBP homologous protein (CHOP), Activating
transcription factor (ATF-4 and -3) induced by PIs. Furthermore, examination of
the PDE4/cAMP-regulated downstream signaling demonstrated the involvement
of PKA. Specifically, cAMP-PKA inhibitor H-89 reversed the rolipram effect of
down-regulating the expression of the PI-induced ER-stress genes. These data
identify an important pathogenic/mechanistic role for PDE4 regulated cAMP-PKA
in the development of HIV-PI induced ER-stress leading to hepatic steatosis and
injury.
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